nct_id,rule_id,rule_type,type,identifier,field,operator,value,unit,raw_text,confidence,parsing_timestamp,condition
NCT04960618,inc001,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,"* Confirmed mycosis fungoides/Sezary syndrome, disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher.",0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,inc002,inclusion,demographic,"[""age""]",age,>=,18,years,Age ≥ 18 years.,0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,inc003,inclusion,condition,"[""general""]",condition,=,,,ECOG Performance Score between 0-1,0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,inc004,inclusion,condition,"[""general""]",condition,=,,,Receipt of at least one prior systemic therapy for MF/SS.,0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,inc005,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment. See section 6.2 Subject,0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,exc001,exclusion,condition,"[""general""]",condition,=,,,for guidelines regarding adjuvant and maintenance therapy for prior malignancy.,0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,exc002,exclusion,condition,"[""general""]",condition,=,,,"Topical or systemic steroids (equivalent to ≤ 10 mg/day of prednisone) may be considered if dose has been constant and discontinuation may lead to rebound flare in disease, adrenal insufficiency, and/",0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,exc003,exclusion,condition,"[""general""]",condition,=,,,Prior therapy with gemcitabine allowed.,0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,exc004,exclusion,condition,"[""general""]",condition,=,,,Refer to Table 1 for laboratory inclusion criteria.,0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,exc005,exclusion,condition,"[""general""]",condition,=,,,The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.,0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,exc006,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,"A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:",0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,exc007,exclusion,condition,"[""general""]",condition,=,,,Not a woman of childbearing potential (WOCBP) as defined in Appendix C,0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,exc008,exclusion,condition,"[""general""]",condition,=,,,A WOCBP who agrees to follow the contraceptive guidance in Appendix C,0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,exc009,exclusion,condition,"[""general""]",condition,=,,,A male participant must agree to use a contraception as detailed in Appendix C of this protocol from screening and through 6 months after the last dose of gemcitabine or 120 days after the last dose o,0.85,2025-11-09T01:47:00.755478,cancer
NCT04960618,exc010,exclusion,condition,"[""general""]",condition,=,,,a: Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks.,0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,inc001,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,* Subjects must have diagnosis of B acute lymphoblastic leukemia harboring the t(9;22) translocation (Philadelphia chromosome positive acute lymphoblastic leukemia \[Ph+ ALL\]) or Ph+ mixed phenotype ,0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,inc002,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Diagnosis of MPAL will only be considered for enrollment during the dose finding period. Participants with MPAL will be enrolled for induction therapy only,0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,inc003,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,All individuals must have a bone marrow biopsy completed during the screening period. Patients with central nervous system (CNS) disease will be included,0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,inc004,inclusion,condition,"[""general""]",condition,=,,,"Expression of CD19 by flow cytometry on bone marrow, if individual has received prior chimeric antigen receptor (CAR) T therapy. If CD19 negative, enrollment may be considered for induction treatment ",0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,inc005,inclusion,condition,"[""general""]",condition,=,,,"Newly diagnosed subjects must have received no prior treatment for their ALL with the exception of steroids (prednisone, dexamethasone), hydrea or IT methotrexate. Individuals may receive pre-treatmen",0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,inc006,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,"Individuals with relapsed disease may not have had prior treatment with dasatinib, however treatment with other tyrosine kinases is permitted",0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,inc007,inclusion,condition,"[""general""]",condition,=,,,"At least 3 half-lives must have passed before cycle 1 day 1 (C1D1) for participants that have used strong CYP3A inhibitors (such as fluconazole, ketoconazole and clarithromycin) prior to enrollment",0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,inc008,inclusion,condition,"[""general""]",condition,=,,,"At least 3 half-lives must have passed before cycle 1 day 3 (C1D3) for participants that have used moderate CYP3A inhibitors (such as fluconazole, ketoconazole and clarithromycin), strong or moderate ",0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,inc009,inclusion,condition,"[""general""]",condition,=,,,At least 4 weeks must have passed before (C1D3) for participants that have recently received a live vaccine,0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,inc010,inclusion,demographic,"[""age""]",age,>=,18,years,Age \>= 18 years. All participants irrespective of their gender identity and members of all races and ethnic groups will be included,0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,exc001,exclusion,condition,"[""general""]",condition,=,,,"* For newly diagnosed subjects: who have received treatment with cytotoxic chemotherapy, radiotherapy or immunotherapy for their ALL/MPAL, or prior dasatinib treatment. For relapsed subjects: prior da",0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,exc002,exclusion,condition,"[""general""]",condition,=,,,Subjects who have received any investigational agents or subjects who are taking investigational or commercial agents or therapies with the intent to treat the subject's malignancy within seven days o,0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,exc003,exclusion,condition,"[""general""]",condition,=,,,"Subjects with chronic myelogenous leukemia (CML) in myeloid blast crisis, Ph+ acute myeloid leukemia (AML) or acute leukemia lineage that cannot be classified based on existing criteria (e.g., from th",0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,exc004,exclusion,condition,"[""general""]",condition,=,,,Subjects with clinically serious infections as determined by the provider requiring ongoing antibiotic therapy. This does not include antibiotic treatment for neutropenic fever,0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,exc005,exclusion,condition,"[""general""]",condition,=,,,Individuals with a pleural or pericardial effusion of any grade,0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,exc006,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,Subjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or other agents used in the study,0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,exc007,exclusion,condition,"[""general""]",condition,=,,,"Subjects who have undergone stem cell transplant must be at least 100 days after transplant, and without active treatment for graft versus host disease (GVHD) other than topical medications",0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,exc008,exclusion,condition,"[""general""]",condition,=,,,"Subjects with uncontrolled cardiac illness including but not limited to, symptomatic congestive heart failure, unstable angina pectoris, clinically significant ventricular arrhythmias (such as ventric",0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,exc009,exclusion,condition,"[""general""]",condition,=,,,Subjects with diagnosed congenital prolonged QT syndrome,0.85,2025-11-09T01:47:00.755478,cancer
NCT04872790,exc010,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Pregnant persons are excluded from this study because dasatinib is a pregnancy category D agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential r,0.85,2025-11-09T01:47:00.755478,cancer
NCT06749210,inc001,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,* Breast Cancer (BC) diagnosis of Stage I-IV including metastatic disease,0.85,2025-11-09T01:47:00.755478,cancer
NCT06749210,inc002,inclusion,condition,"[""general""]",condition,=,,,completed taxane-based chemotherapy for BC at least 3 months ago (no limit on how long ago),0.85,2025-11-09T01:47:00.755478,cancer
NCT06749210,inc003,inclusion,condition,"[""general""]",condition,=,,,symptomatic for chemotherapy-induced neuropathy (self-report),0.85,2025-11-09T01:47:00.755478,cancer
NCT06749210,inc004,inclusion,condition,"[""general""]",condition,=,,,postural control score that indicates potential fall-risk,0.85,2025-11-09T01:47:00.755478,cancer
NCT06749210,inc005,inclusion,condition,"[""general""]",condition,=,,,able to understand and comply with directions associated with testing and study treatments,0.85,2025-11-09T01:47:00.755478,cancer
NCT06749210,exc001,exclusion,condition,"[""general""]",condition,=,,,* pre-existing vestibular dysfunction,0.85,2025-11-09T01:47:00.755478,cancer
NCT06749210,exc002,exclusion,condition,"[""general""]",condition,=,,,poorly controlled diabetes (hgA1C\>=8),0.85,2025-11-09T01:47:00.755478,cancer
NCT06749210,exc003,exclusion,condition,"[""general""]",condition,=,,,non-ambulatory (assistive and prosthetic devices allowed),0.85,2025-11-09T01:47:00.755478,cancer
NCT06749210,exc004,exclusion,condition,"[""general""]",condition,=,,,hearing impairment resulting in less than 10% hearing bilaterally,0.85,2025-11-09T01:47:00.755478,cancer
NCT06749210,exc005,exclusion,condition,"[""general""]",condition,=,,,"contraindication to participate in the experimental physical activity per the treating oncologist due to additional condition (e.g., herniated disc, unstable bone metastases)",0.85,2025-11-09T01:47:00.755478,cancer
NCT06749210,exc006,exclusion,condition,"[""general""]",condition,=,,,"currently in activity-based therapy (e.g., physical therapy, occupational therapy). May enroll if still meet eligibility criteria once activity-based therapy is complete.",0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,inc001,inclusion,condition,"[""general""]",condition,=,,,* Documented informed consent of the participant and/or legally authorized representative.,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,inc002,inclusion,condition,"[""general""]",condition,=,,,"Assent, when appropriate, will be obtained per institutional guidelines",0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,inc003,inclusion,condition,"[""general""]",condition,=,,,Agreement to allow the use of archival tissue from diagnostic tumor biopsies,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,inc004,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,"Karnofsky Performance Status (KPS) \>= 60% except for loss of mobility due to disease involvement; e.g., confinement to a wheelchair due to spinal cord compression",0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,inc005,inclusion,condition,"[""general""]",condition,=,,,Life expectancy \> 4 weeks,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,inc006,inclusion,condition,"[""general""]",condition,=,,,Participant has a prior histologically-confirmed malignant brain neoplasm and has progressed after prior conventional therapy,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,inc007,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Radiographic evidence of progression/recurrence of the measurable disease more than 12 weeks after the end of the initial conventional therapy (including initial radiation therapy),0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,inc008,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,City of Hope (COH) clinical pathology confirms IL13Ralpha2+ tumor expression by immunohistochemistry (IHC) at the initial tumor presentation or recurrent disease (H-score \>= 50),0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,inc009,inclusion,condition,"[""general""]",condition,=,,,"If the participant has a shunt, it must be programmable and the participant must be able to tolerate the shunt being switched off for at least 2 consecutive days",0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,inc010,inclusion,condition,"[""general""]",condition,=,,,"Platelets \>= 50,000/mm\^3 (performed within 6 weeks of signing the main informed consent)",0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,exc001,exclusion,condition,"[""general""]",condition,=,,,* Pulmonary: Research participant requires supplemental oxygen to keep saturation greater than 95% and the situation is not expected to resolve within 2 weeks,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,exc002,exclusion,condition,"[""general""]",condition,=,,,Cardiac: Research participant requires pressor support and/or has symptomatic cardiac arrhythmias,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,exc003,exclusion,condition,"[""general""]",condition,=,,,Renal: Research participant requires dialysis,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,exc004,exclusion,condition,"[""general""]",condition,=,,,Neurologic: Research participant has uncontrolled seizure activity and/or clinically evident progressive encephalopathy,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,exc005,exclusion,condition,"[""general""]",condition,=,,,Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study. A legal guardian may substitute for the research part,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,exc006,exclusion,condition,"[""general""]",condition,=,,,"Research participant with any non-malignant intercurrent illness which is either poorly controlled with currently available treatment, or which is of such severity that the study team deems it unwise ",0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,exc007,exclusion,condition,"[""general""]",condition,=,,,Research participant with any other active malignancies,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,exc008,exclusion,condition,"[""general""]",condition,=,,,Research participant being treated for severe infection or recovering from major surgery is ineligible until recovery is deemed complete by the study team,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,exc009,exclusion,condition,"[""general""]",condition,=,,,Research participant with any uncontrolled illness including ongoing or active infection. Research participant with known active hepatitis B or C infection; research participant with any signs or symp,0.85,2025-11-09T01:47:00.755478,cancer
NCT04510051,exc010,exclusion,condition,"[""general""]",condition,=,,,Research participant who has confirmed HIV positivity within 4 weeks of enrollment,0.85,2025-11-09T01:47:00.755478,cancer
NCT00598351,inc001,inclusion,condition,"[""general""]",condition,=,,,"To be eligible for entry into the study, candidates must meet all the following criteria:",0.85,2025-11-09T01:47:00.755478,cancer
NCT00598351,inc002,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Have the diagnosis of NF2 by established clinical criteria or genetic testing.,0.85,2025-11-09T01:47:00.755478,cancer
NCT00598351,inc003,inclusion,demographic,"[""age""]",age,=,,,Be between the age of 8 and 75.,0.85,2025-11-09T01:47:00.755478,cancer
NCT00598351,inc004,inclusion,condition,"[""general""]",condition,=,,,Have the capacity to undergo serial MRI scanning of the CNS without IV sedation.,0.85,2025-11-09T01:47:00.755478,cancer
NCT00598351,inc005,inclusion,condition,"[""general""]",condition,=,,,"Able to give informed consent, or have a parent able to provide informed consent if a child.",0.85,2025-11-09T01:47:00.755478,cancer
NCT00598351,exc001,exclusion,condition,"[""general""]",condition,=,,,Candidates will be excluded if they:,0.85,2025-11-09T01:47:00.755478,cancer
NCT00598351,exc002,exclusion,condition,"[""general""]",condition,=,,,"Have a clinically unstable condition that precludes serial clinical and imaging evaluation (i.e. Class 3 congestive heart failure, severe chronic renal insufficiency, severe chronic obstructive pulmon",0.85,2025-11-09T01:47:00.755478,cancer
NCT00598351,exc003,exclusion,condition,"[""general""]",condition,=,,,"Cannot have an MRI scan due to an allergy or relative contraindication to MRI contrast agents, prior surgery or implant that involves metal clips or wires, which might be expected to cause tissue dama",0.85,2025-11-09T01:47:00.755478,cancer
NCT00598351,exc004,exclusion,condition,"[""general""]",condition,=,,,ABIs or cochlear implants are not approved by the NIH Radiology department for safe use on NIH scanners..,0.85,2025-11-09T01:47:00.755478,cancer
NCT00598351,exc005,exclusion,condition,"[""general""]",condition,=,,,"Have severe chronic renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73 m2), hepatorenal syndrome or post-liver transplantation.",0.85,2025-11-09T01:47:00.755478,cancer
NCT00598351,exc006,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Are pregnant at time of intake visit (women of childbearing age will be tested with a urine pregnancy test).,0.85,2025-11-09T01:47:00.755478,cancer
NCT06129539,inc001,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,1. Diagnosis of central precocious puberty.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,inc002,inclusion,demographic,"[""age""]",age,=,,,"Onset of development of sex characteristics (i.e., breast development in girls or testicular enlargement in boys according to the Tanner method) before the age of 8 years in girls and 9 years in boys.",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,inc003,inclusion,condition,"[""general""]",condition,=,,,"Initially, only participants aged (a) 5 to 8 years inclusive (i.e., \<9 years) are eligible. The Sponsor will determine based on the recommendation of the DMC following the interim analysis whether pa",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,inc004,inclusion,condition,"[""general""]",condition,=,,,Participant to receive at least 1 year of gonadotropin-releasing hormone agonist (GnRHa) therapy from study treatment start.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,inc005,inclusion,condition,"[""general""]",condition,=,,,"(a) Pre-treated participants: Start of initial GnRHa therapy no later than 18 months after onset of the first signs of CPP.

   (b) Treatment-naive participants: Start of Debio 4326 treatment no later",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,inc006,inclusion,demographic,"[""age""]",age,>=,1,years,"(a) Pre-treated participants: Difference between bone age (Greulich and Pyle method) and chronological age of ≥1 year based on historical values at the initiation of the GnRHa therapy.

   (b) Treatme",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,inc007,inclusion,condition,"[""general""]",condition,=,,,"(a) Pre-treated participants: Pubertal-type LH response (LH ≥6 IU/L) following a GnRH/GnRHa stimulation test, or random non-stimulated serum LH \>0.5 IU/L (if considered local standard of care), based",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,inc008,inclusion,condition,"[""general""]",condition,=,,,"(a) Pre-treated participants: Clinical evidence of puberty, defined as Tanner Staging ≥2 for breast development for girls and testicular volume ≥4 milliliter (mL) (cubic centimeter \[cc\]) for boys, p",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,exc001,exclusion,condition,"[""general""]",condition,=,,,1. Gonadotropin-independent (peripheral) precocious puberty: gonadotropin-independent gonadal or adrenal sex steroid secretion.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,exc002,exclusion,condition,"[""general""]",condition,=,,,"(a) Pre-treated participants: Non-progressing, isolated premature thelarche prior to the initial GnRHa therapy.

   (b) Treatment-naive participants: Non-progressing, isolated premature thelarche.",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,exc003,exclusion,condition,"[""general""]",condition,=,,,Presence of an unstable intracranial tumor or an intracranial tumor potentially requiring neurosurgery or cerebral irradiation. Participants with hamartomas not requiring surgery are eligible.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,exc004,exclusion,condition,"[""general""]",condition,=,,,"Any other condition or chronic illness possibly interfering with growth (e.g., renal failure, diabetes, moderate to severe scoliosis, previously treated intracranial tumor).",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,exc005,exclusion,condition,"[""general""]",condition,=,,,"Other than GnRHa therapy in pre-treated participants, any ongoing treatment with a potential effect on serum levels of gonadotropins or sex steroids, or possibly interfering with growth, opioids, cent",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,exc006,exclusion,condition,"[""general""]",condition,=,,,"Prior or current therapy with medroxyprogesterone acetate, growth hormone, or Insulin-like growth factor-1 (IGF-1).",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,exc007,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Diagnosis of short stature, i.e., more than 2.25 standard deviations (SD) below the mean height-for-age.",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,exc008,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Known history of seizures, epilepsy, and/or central nervous system disorders that may have been associated with seizures or convulsions.",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,exc009,exclusion,condition,"[""general""]",condition,=,,,Prior (within 2 months of study treatment start) or current use of medications that have been associated with seizures or convulsions.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06129539,exc010,exclusion,condition,"[""general""]",condition,=,,,"Use of anticoagulants (heparin or coumarin derivatives).

Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.",0.85,2025-11-09T01:47:00.755478,diabetes
NCT04641702,inc001,inclusion,demographic,"[""age""]",age,=,,,"1. Male or female patients, age 18 and above.",0.85,2025-11-09T01:47:00.755478,diabetes
NCT04641702,inc002,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,"Evaluated by Emory Digestive Diseases Clinic, Emory Motility Lab, the Emory Endoscopy Unit, or Emory Surgery Department from October 1, 2020, to September 30, 2024.",0.85,2025-11-09T01:47:00.755478,diabetes
NCT04641702,inc003,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,Has a diagnosis of achalasia or an esophageal motility disorder with confirmed evaluation by one of the following modalities: functional lumen imaging probe (FLIP) or high-resolution esophageal manome,0.85,2025-11-09T01:47:00.755478,diabetes
NCT04641702,inc004,inclusion,condition,"[""general""]",condition,=,,,Undergoing a diagnostic Functional Lumen Imaging Probe (FLIP) study at Emory University Hospital with anesthesia assistance (for Aim 1),0.85,2025-11-09T01:47:00.755478,diabetes
NCT04641702,inc005,inclusion,condition,"[""general""]",condition,=,,,Undergoing Heller myotomy or per oral endoscopic myotomy for the treatment of their esophageal motility disorder (for Aim 2),0.85,2025-11-09T01:47:00.755478,diabetes
NCT04641702,exc001,exclusion,condition,"[""general""]",condition,=,,,1. Patients younger than 18 years old,0.85,2025-11-09T01:47:00.755478,diabetes
NCT04641702,exc002,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Pregnant women,0.85,2025-11-09T01:47:00.755478,diabetes
NCT04641702,exc003,exclusion,condition,"[""general""]",condition,=,,,Non-English speaking - the rationale is that the symptom characterization and outcome data are measured on detailed and fairly lengthy (5-7 pages) of questionnaires written in English with some medica,0.85,2025-11-09T01:47:00.755478,diabetes
NCT04641702,exc004,exclusion,condition,"[""general""]",condition,=,,,Cognitively impaired adults unable to provide informed consent,0.85,2025-11-09T01:47:00.755478,diabetes
NCT04641702,exc005,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Cardiac disease in the form of - arrhythmia requiring ICD or pacemaker, baseline bradycardia with HR \<60 or tachycardia with HR \> 90, congestive heart failure with ejection fraction \<35%, history o",0.85,2025-11-09T01:47:00.755478,diabetes
NCT07128095,inc001,inclusion,demographic,"[""gender""]",gender,=,all,,Male and female participants. Are between the ages of 18-75. Have a resting blood pressure no higher than 150/90 (stage 2 hypertension). Have a BMI below 35 kg/m2 (otherwise healthy). Free from metabo,0.85,2025-11-09T01:47:00.755478,diabetes
NCT07128095,exc001,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,"Younger than 18 or older than 30. Have a resting blood pressure \> 150/90. Have a BMI \> 35 Kg/m2 or \< 18 Kg/m2. History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., C",0.85,2025-11-09T01:47:00.755478,diabetes
NCT07095673,inc001,inclusion,demographic,"[""age""]",age,=,,,* Adults over the age of 19,0.85,2025-11-09T01:47:00.755478,diabetes
NCT07095673,inc002,inclusion,condition,"[""general""]",condition,=,,,BMI of \> 25,0.85,2025-11-09T01:47:00.755478,diabetes
NCT07095673,exc001,exclusion,condition,"[""general""]",condition,=,,,* Adults with BMI of less than 25,0.85,2025-11-09T01:47:00.755478,diabetes
NCT07095673,exc002,exclusion,condition,"[""general""]",condition,=,,,Adults who are not active:,0.85,2025-11-09T01:47:00.755478,diabetes
NCT07095673,exc003,exclusion,condition,"[""general""]",condition,=,,,with activity participation limitations,0.85,2025-11-09T01:47:00.755478,diabetes
NCT07095673,exc004,exclusion,condition,"[""general""]",condition,=,,,"with disability (physical, mental)",0.85,2025-11-09T01:47:00.755478,diabetes
NCT07095673,exc005,exclusion,condition,"[""general""]",condition,=,,,"impairment (vision, hearing and memory loss, cognitive)",0.85,2025-11-09T01:47:00.755478,diabetes
NCT07095673,exc006,exclusion,condition,"[""general""]",condition,=,,,Alzheimer's disease (AD).,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,inc001,inclusion,condition,"[""general""]",condition,=,,,* Both males and females of all race/ethnic groups are eligible for participation in this study.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,inc002,inclusion,demographic,"[""age""]",age,=,,,at least 18 years of age. The investigators will not limit enrollment based on an upper age provided that the participant meets the other eligibility requirements.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,inc003,inclusion,condition,"[""general""]",condition,=,,,"Body mass index (BMI) of at least 25.0 kg/m2. The investigators will not limit enrollment based on an upper BMI level provided that the participant meets the other eligibility requirements. However, m",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,inc004,inclusion,condition,"[""general""]",condition,=,,,Ability to provide informed consent prior to participation in this study.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,inc005,inclusion,condition,"[""general""]",condition,=,,,Ability to provide clearance from their primary care physician to engage in the diet and physical activity components of the weight loss intervention.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,exc001,exclusion,condition,"[""general""]",condition,=,,,* Report moderate-to-vigorous exercise on \&gt;3 days/week or a total of \&gt;60 min/week over the past 3 months.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,exc002,exclusion,condition,"[""general""]",condition,=,,,Engaging in any style of yoga on an average of at least 1 day/week over the past 3 months.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,exc003,exclusion,condition,"[""general""]",condition,=,,,Report weight loss of 3% or more or participating in a weight reduction diet in the past 3 months.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,exc004,exclusion,condition,"[""general""]",condition,=,,,Currently prescribed an anti-obesity medication.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,exc005,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Females who are pregnant or breastfeeding or reporting a planned pregnancy during the study period.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,exc006,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of bariatric surgery.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,exc007,exclusion,condition,"[""general""]",condition,=,,,Report a current medical condition or treatment for a medical condition that could affect body weight.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,exc008,exclusion,condition,"[""general""]",condition,=,,,"Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction, coronary artery bypass grafti",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,exc009,exclusion,condition,"[""general""]",condition,=,,,"Resting systolic blood pressure of 160 mmHg or more or resting diastolic blood pressure of 100 mmHg or more. If medicated for blood pressure control, the medication dose needs to be stable for at leas",0.85,2025-11-09T01:47:00.755478,diabetes
NCT06636773,exc010,exclusion,condition,"[""general""]",condition,=,,,Eating disorders that would contraindicate weight loss or physical activity.,0.85,2025-11-09T01:47:00.755478,diabetes
NCT05011045,inc001,inclusion,demographic,"[""age""]",age,=,,,* Age 18 years or older,0.85,2025-11-09T01:47:00.755478,dementia
NCT05011045,inc002,inclusion,condition,"[""general""]",condition,=,,,"Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myelom",0.85,2025-11-09T01:47:00.755478,dementia
NCT05011045,inc003,inclusion,condition,"[""general""]",condition,=,,,Proficient and capable of completing tests in English,0.85,2025-11-09T01:47:00.755478,dementia
NCT05011045,inc004,inclusion,condition,"[""general""]",condition,=,,,Patients with claustrophobia are eligible if the claustrophobia is managed with medication,0.85,2025-11-09T01:47:00.755478,dementia
NCT05011045,inc005,inclusion,condition,"[""general""]",condition,=,,,Patients with cognitively-impairment are eligible if the impairment is managed with medication,0.85,2025-11-09T01:47:00.755478,dementia
NCT05011045,inc006,inclusion,condition,"[""general""]",condition,=,,,Patients who are pregnant,0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,inc001,inclusion,condition,"[""general""]",condition,=,,,"* Healthy individuals with no history of neurological, speech, or hearing disorders (other than stuttering in studies that involve adults who stutter).",0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,inc002,inclusion,condition,"[""general""]",condition,=,,,"To maximize the uniformity of prior exposure to the speech stimuli that will be used, only native speakers of American English will be recruited, and only those with limited exposure to a second langu",0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,inc003,inclusion,condition,"[""general""]",condition,=,,,"All adult participants will also pass a standard pure-tone hearing screening at a 25dB hearing level threshold at 500, 1k, 2k, and 4kHz frequencies.",0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,inc004,inclusion,condition,"[""general""]",condition,=,,,"All participating children will pass a hearing screening at a 20 dB threshold at 500, 1k, 2k, and 4k Hz.",0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,inc005,inclusion,condition,"[""general""]",condition,=,,,Participants in experiments that require them to read orthographic stimuli must have normal or corrected-to-normal vision (MRI-safe corrective glasses are available at the Boston University Cognitive ,0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,inc006,inclusion,demographic,"[""age""]",age,=,,,"Participating children will complete additional speech, language, hearing, and cognitive tests to ensure that they are within normal performance ranges for their age with the exception of stuttering f",0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,inc007,inclusion,condition,"[""general""]",condition,=,,,Persons who stutter will be evaluated formally by a speech-language pathologist to assess stuttering severity and to ensure the absence of other speech or language disorders. PWS will have no history ,0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,inc008,inclusion,condition,"[""general""]",condition,=,,,Participants with primary progressive aphasia (PPA) will have been diagnosed through the Massachusetts General Hospital Frontotemporal Disorders Unit (MGH-FTD) by an experienced neurologist in coordin,0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,inc009,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,"Participants with PPA will have a score of 1.0 or lower on the Clinical Dementia Rating scale (i.e., mild cognitive impairment or mild dementia) to ensure cognitive levels are sufficient to complete t",0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,inc010,inclusion,condition,"[""general""]",condition,=,,,All participants with PPA must have a recent clinical assessment and T1 structural neuroimaging scan through the MGH-FTD Unit for eligibility for this study.,0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,exc001,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,"* Participants in studies that involve tDCS or MRI scanning will have no contraindications specific to those procedures. For the tDCS study, this includes individuals who have a metallic implant in th",0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,exc002,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,"For MRI studies, this includes a history of seizures, severe claustrophobia, the presence of magnetically or mechanically active implant, ferromagnetic material embedded in any part of the body, or pr",0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,exc003,exclusion,condition,"[""general""]",condition,=,,,All participants will perform a standardized nonword repetition pre-test (the Dollaghan and Campbell Nonword Repetition Task) to assess working memory performance. Participants who perform more than 2,0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,exc004,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Participating children will have no history of neurological disorder other than stuttering, and will demonstrate very mild to severe stuttering according to the Stuttering Severity Instrument for Chil",0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,exc005,exclusion,condition,"[""general""]",condition,=,,,Children under the age of 6 and over the age of 8 will not enrolled in this study.,0.85,2025-11-09T01:47:00.755478,dementia
NCT05437159,exc006,exclusion,condition,"[""general""]",condition,=,,,Participants with PPA will not be eligible for this study if they are taking any medications that would be expected to affect speech or language.,0.85,2025-11-09T01:47:00.755478,dementia
NCT01818661,inc001,inclusion,condition,"[""general""]",condition,=,,,* We will study subjects that fulfill clinical inclusion criteria for neurodegenerative AOS that have been seen and diagnosed at Mayo Clinic,0.85,2025-11-09T01:47:00.755478,dementia
NCT01818661,exc001,exclusion,condition,"[""general""]",condition,=,,,"* Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes will be excluded.",0.85,2025-11-09T01:47:00.755478,dementia
NCT01818661,exc002,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Women that are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan.,0.85,2025-11-09T01:47:00.755478,dementia
NCT01818661,exc003,exclusion,condition,"[""general""]",condition,=,,,"Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies",0.85,2025-11-09T01:47:00.755478,dementia
NCT01818661,exc004,exclusion,condition,"[""general""]",condition,=,,,"Subjects will also be excluded if they do not have an informant, or do not consent to research.",0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,inc001,inclusion,condition,"[""general""]",condition,=,,,Group 1: Cognitively Normal (CN),0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,inc002,inclusion,condition,"[""general""]",condition,=,,,No subjective complaints of cognitive impairment,0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,inc003,inclusion,condition,"[""general""]",condition,=,,,"No cognitive impairment evident on formal testing interpreted by expert adjudication committee (typically, performance not worse than 1 SD below demographically relevant norms)",0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,inc004,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,Clinical Dementia Rating (CDR) = 0 or 0.5,0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,inc005,inclusion,labvalue,"[""test""]",value,=,,,Normal glycemic control as indicated by American Diabetes Association (ADA) guidelines for normal 2 hour glycemic response to a glucose tolerance test (\< 140 mg/dL).,0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,inc006,inclusion,condition,"[""general""]",condition,=,,,"Reliable collateral or study partner available to attend Visit 1 at a minimum

Group 2: Mild Cognitive Impairment (MCI)",0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,inc007,inclusion,condition,"[""general""]",condition,=,,,Objective evidence of memory and/or executive function deficits on neuropsychological testing (typically 1.5 SD below demographically relevant norms),0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,inc008,inclusion,condition,"[""general""]",condition,=,,,CDR = 0 or 0.5,0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,inc009,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,"Reliable collateral or study partner

Group 3: Alzheimer's Disease (AD)",0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,inc010,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,"Diagnosis of probable mild AD, diagnosed with NIA-AA criteria, or mixed AD and vascular pathology as long as there is not a large vessel territory stroke, adjudicated by expert consensus panel.",0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,exc001,exclusion,condition,"[""general""]",condition,=,,,1. Clinically significant abnormal labs,0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,exc002,exclusion,condition,"[""general""]",condition,=,,,"Significant neurologic disease that might affect cognition, other than AD, such as stroke, Parkinson's disease, multiple sclerosis, or recent severe head injury with loss of consciousness for more tha",0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,exc003,exclusion,condition,"[""general""]",condition,=,,,"Clinically significant medical illness or organ failure as determined by study clinicians, including severe, uncontrolled cardiovascular disease, oxygen-treated chronic obstructive pulmonary disease, ",0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,exc004,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,Current substance abuse or heavy alcohol consumption defined as \>14 alcoholic drinks per week; or history of alcoholism or substance abuse within previous 10 years,0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,exc005,exclusion,condition,"[""general""]",condition,=,,,Current poorly controlled depression or other psychiatric illness as determined by clinical judgement of study clinicians or neuropsychologists,0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,exc006,exclusion,condition,"[""general""]",condition,=,,,"Current use of anti-psychotic, benzodiazepines (PRN use \<3 times per week is acceptable), anti-coagulants (for participants who will receive a lumbar puncture), strongly anticholinergic or sedative m",0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,exc007,exclusion,condition,"[""general""]",condition,=,,,Use of anticonvulsant for seizure disorder. (Use of anticonvulsant to treat other illnesses will be reviewed by the study MD and eligibility will be determined on a case by case basis.),0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,exc008,exclusion,condition,"[""general""]",condition,=,,,Current use of insulin,0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,exc009,exclusion,condition,"[""general""]",condition,=,,,"Brain MRI contraindications; including use of pacemakers, aneurysm clips, artificial heart valves, ear implants or metal/foreign objects in the eyes will be excluded from MRI",0.85,2025-11-09T01:47:00.755478,dementia
NCT03140865,exc010,exclusion,condition,"[""general""]",condition,=,,,"For participants completing any brain imaging protocol, inability to lie on the scanner bed for 40 minutes, or claustrophobia",0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,inc001,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,Dementia caregiver living with person with dementia,0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,inc002,inclusion,condition,"[""general""]",condition,=,,,"willing to be randomized, 4. read/understand English",0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,inc003,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,insomnia diagnosis,0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,inc004,inclusion,condition,"[""general""]",condition,=,,,"no prescribed or over-the-counter sleep meds or stabilized 6+ weeks.

Insomnia:",0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,inc005,inclusion,condition,"[""general""]",condition,=,,,complaints for 6+ mos,0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,inc006,inclusion,condition,"[""general""]",condition,=,,,adequate opportunity and circumstances for sleep,0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,inc007,inclusion,condition,"[""general""]",condition,=,,,"1+ of the following: difficulty falling asleep, staying asleep, or waking too early",0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,inc008,inclusion,condition,"[""general""]",condition,=,,,"daytime dysfunction (mood, cognitive, social, occupational) due to insomnia",0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,inc009,inclusion,condition,"[""general""]",condition,=,,,Screening interview indicates Insomnia Severity Index score ≥11 or Insomnia Severity Index score 9-10,0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,inc010,inclusion,condition,"[""general""]",condition,=,,,baseline diaries indicate \>30 mins of sleep onset latency or wake after sleep onset on 3+ nts.,0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,exc001,exclusion,condition,"[""general""]",condition,=,,,* unable to consent,0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,exc002,exclusion,condition,"[""general""]",condition,=,,,cognitive impairment \[Telephone Interview for Cognitive Status (TICS) \<25 or Mini Mental State Examination (MMSE) \<26\],0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,exc003,exclusion,condition,"[""general""]",condition,=,,,"sleep disorder other than insomnia \[i.e., sleep apnea (apnea/hypopnea index, AHI \>15)\]",0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,exc004,exclusion,condition,"[""general""]",condition,=,,,bipolar or seizure disorder,0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,exc005,exclusion,condition,"[""general""]",condition,=,,,"other major psychopathology except depression or anxiety (e.g., suicidal ideation/intent, psychosis)",0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,exc006,exclusion,condition,"[""general""]",condition,=,,,severe untreated psychiatric comorbidity,0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,exc007,exclusion,condition,"[""general""]",condition,=,,,"psychotropic or other medications (e.g., beta-blockers) that alter sleep",0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,exc008,exclusion,condition,"[""general""]",condition,=,,,"non-pharmacological tx for sleep or mood outside current trial.

PERSONS WITH DEMENTIA

Inclusion Criteria:",0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,exc009,exclusion,condition,"[""general""]",condition,=,,,Persons with dementia living with caregiver,0.85,2025-11-09T01:47:00.755478,dementia
NCT04632628,exc010,exclusion,condition,"[""general""]",condition,=,,,Have an eligible caregiver,0.85,2025-11-09T01:47:00.755478,dementia
NCT04380831,inc001,inclusion,condition,"[""general""]",condition,=,,,* Karnofsky performance status (KPS) \>= 70,0.85,2025-11-09T02:20:29.746530,cancer
NCT04380831,inc002,inclusion,condition,"[""general""]",condition,=,,,Systemic sclerosis patients evaluated within 30 days of start of conditioning regimen who would be candidates for TBI-cyclophosphamide (Cy) per City of Hope (COH) guidelines and standard operating pro,0.85,2025-11-09T02:20:29.746530,cancer
NCT04380831,inc003,inclusion,condition,"[""general""]",condition,=,,,Patients must be suitable for TBI conditioning regimens as part of transplant per radiation the referring hematologist,0.85,2025-11-09T02:20:29.746530,cancer
NCT04380831,inc004,inclusion,condition,"[""general""]",condition,=,,,Patients must have adequate organ function for HCT as determined by the hematologist,0.85,2025-11-09T02:20:29.746530,cancer
NCT04380831,inc005,inclusion,condition,"[""general""]",condition,=,,,Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration,0.85,2025-11-09T02:20:29.746530,cancer
NCT04380831,inc006,inclusion,condition,"[""general""]",condition,=,,,All subjects must have the ability to understand the treatment and the willingness to sign a written informed consent,0.85,2025-11-09T02:20:29.746530,cancer
NCT04380831,exc001,exclusion,condition,"[""general""]",condition,=,,,* Patients should not have any uncontrolled illness including ongoing or active infection,0.85,2025-11-09T02:20:29.746530,cancer
NCT04380831,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,Prior history of radiation therapy must be presented to study principal investigator (PI) for eligibility determination,0.85,2025-11-09T02:20:29.746530,cancer
NCT04380831,exc003,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Pregnant women are excluded from this study because total body irradiation is an agent with the potential for teratogenic or abortifacient effects,0.85,2025-11-09T02:20:29.746530,cancer
NCT04380831,exc004,exclusion,condition,"[""general""]",condition,=,,,"Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study",0.85,2025-11-09T02:20:29.746530,cancer
NCT06450353,inc001,inclusion,demographic,"[""age""]",age,>=,18,years,1. ≥ 18 years of age.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06450353,inc002,inclusion,condition,"[""general""]",condition,=,,,Candidate for allogeneic transplantation,0.85,2025-11-09T02:20:29.746530,cancer
NCT06450353,exc001,exclusion,condition,"[""general""]",condition,=,,,1\) Allogeneic stem cell transplantation not medically indicated.,0.85,2025-11-09T02:20:29.746530,cancer
NCT07166601,inc001,inclusion,condition,"[""general""]",condition,=,,,Part 1- M0324 Monotherapy:,0.85,2025-11-09T02:20:29.746530,cancer
NCT07166601,inc002,inclusion,condition,"[""general""]",condition,=,,,Participants with certain advanced/metastatic solid tumor types known to overexpress MUC-1 and who are intolerant or refractory to standard therapy or for which no standard therapy is judged appropria,0.85,2025-11-09T02:20:29.746530,cancer
NCT07166601,inc003,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Participants with certain advanced/metastatic tumor types known to overexpress MUC-1 and the participants in the combination treatment involving M0324 and pembrolizumab must be intolerant or refractor,0.85,2025-11-09T02:20:29.746530,cancer
NCT07166601,inc004,inclusion,condition,"[""general""]",condition,=,,,"Participants with previously untreated metastatic pancreatic ductal adenocarcinoma, who are judged by Investigator as eligible for treatment with mFOLFIRINOX. Participants with prior Whipple surgery a",0.85,2025-11-09T02:20:29.746530,cancer
NCT07166601,inc005,inclusion,condition,"[""general""]",condition,=,,,Other protocol defined inclusion criteria could apply,0.85,2025-11-09T02:20:29.746530,cancer
NCT07166601,exc001,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"* Has a history of chronic diarrhea greater than or equal to (\>=) Grade 2, inflammatory disease of the colon or rectum, or unresolved partial or complete intestinal obstruction",0.85,2025-11-09T02:20:29.746530,cancer
NCT07166601,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,Participant has a history of malignancy within 3 years before the date of enrollment,0.85,2025-11-09T02:20:29.746530,cancer
NCT07166601,exc003,exclusion,condition,"[""general""]",condition,=,,,"Uncontrolled or poorly controlled arterial hypertension, uncontrolled cardiac arrhythmia, unstable angina, myocardial infarction, congestive heart failure \[New York Heart Association (NYHA) \>= II\] ",0.85,2025-11-09T02:20:29.746530,cancer
NCT07166601,exc004,exclusion,condition,"[""general""]",condition,=,,,Life expectancy of less than 3 months,0.85,2025-11-09T02:20:29.746530,cancer
NCT07166601,exc005,exclusion,condition,"[""general""]",condition,=,,,Other protocol defined exclusion criteria could apply,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,inc001,inclusion,condition,"[""general""]",condition,=,,,* Willing to review and sign written informed consent.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,inc002,inclusion,demographic,"[""age""]",age,>,18,years,Male or female patients age \> 18 years.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,inc003,inclusion,condition,"[""general""]",condition,=,,,Tissue confirmation of head and neck squamous cell carcinoma.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,inc004,inclusion,condition,"[""general""]",condition,=,,,Patients for whom a potentially curative resection is planned as standard of care.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,inc005,inclusion,condition,"[""general""]",condition,=,,,ECOG performance status of 0 or 1,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,inc006,inclusion,demographic,"[""age""]",age,=,,,"Adequate hematologic and end-organ function appropriate for surgery as determined by routine preoperative evaluation. If liver function, renal function and hematologic laboratory test results are acce",0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,inc007,inclusion,condition,"[""general""]",condition,=,,,For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods as defined below:,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,inc008,inclusion,condition,"[""general""]",condition,=,,,"A woman is considered to be of childbearing potential if she is post-menarchal, has not reached a postmenopausal state (12 continuous months of amenorrhea with no identified cause other than menopause",0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,inc009,inclusion,demographic,"[""age""]",age,>,55,years,age \>55 years old,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,inc010,inclusion,demographic,"[""age""]",age,<,55,years,age \<55 years or less and,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,exc001,exclusion,condition,"[""general""]",condition,=,,,* Patients not eligible for standard of care surgical resection,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,Patients with a history of infusion reactions or allergic reactions to panitumumab.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,exc003,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening che",0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,exc004,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of radiation pneumonitis in the radiation field (fibrosis) is permitted.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,exc005,exclusion,condition,"[""general""]",condition,=,,,Active tuberculosis. Patients do NOT have to be screened for tuberculosis for this trial.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,exc006,exclusion,condition,"[""general""]",condition,=,,,"Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of s",0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,exc007,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,exc008,exclusion,condition,"[""general""]",condition,=,,,"Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. The following drugs are known to interact with panitumumab and therefore any",0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,exc009,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,"Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of study treatment.",0.85,2025-11-09T02:20:29.746530,cancer
NCT06819228,exc010,exclusion,condition,"[""general""]",condition,=,,,"Magnesium or phosphorus lower than normal institutional values, patient is symptomatic, and the values are unable to be corrected through standard repletion strategies.",0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,inc001,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,* Provision of formalin-fixed paraffin embedded tissue sample from primary or metastatic disease,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,inc002,inclusion,condition,"[""general""]",condition,=,,,Karnofsky Performance Score of ≥60.,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,inc003,inclusion,condition,"[""general""]",condition,=,,,Additional Inclusion Criteria Specific for Arm A and Japan:,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,inc004,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Histologically proven diagnosis of GBM. Patients who have had RT for low-grade glioma (LGG) or grade 3 glioma and have subsequently relapsed to histologically confirmed GBM can be considered,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,inc005,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,A radiological diagnosis of recurrent/relapsed or progressive disease according to RANO criteria.,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,inc006,inclusion,condition,"[""general""]",condition,=,,,Completion of first-line radiation at least 6 months prior to Cycle 1 Day 1.,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,inc007,inclusion,condition,"[""general""]",condition,=,,,Patients with tumor-induced seizures must be well controlled on a stable anti-epileptic treatment,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,inc008,inclusion,condition,"[""general""]",condition,=,,,Willing to receive anti-epileptic prophylaxis for the duration of study drug administration.,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,inc009,inclusion,condition,"[""general""]",condition,=,,,"Additional Inclusion Criteria Specific for Arm B:

\*\*Arm B has now closed to recruitment\*\*",0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,inc010,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Histologically proven diagnosis of solid tumor malignancy and Magnetic Resonance (MR) imaging documenting brain lesions.,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,exc001,exclusion,condition,"[""general""]",condition,=,,,* Administration of chemotherapy or any investigational drug in the 28 days or carmustine (CCNU) or lomustine (BCNU) in the 6 weeks prior to receiving the first dose of treatment in Arms A and C. Admi,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of severe brain-injury or stroke.,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,exc003,exclusion,condition,"[""general""]",condition,=,,,Patient not eligible for sequential MRI evaluations are not eligible for this study.,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,exc004,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of epileptic disorder or any seizure history unrelated to tumor,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,exc005,exclusion,condition,"[""general""]",condition,=,,,Treatment with Strong inhibitors or inducers of CYP3A4 within 2 weeks prior to receiving study drug,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,exc006,exclusion,condition,"[""general""]",condition,=,,,Concurrent therapy with other seizurogenic medications.,0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,exc007,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.",0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,exc008,exclusion,condition,"[""general""]",condition,=,,,"Concurrent severe and/or uncontrolled medical condition (e.g., severe COPD).",0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,exc009,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Prior treatment with pneumotoxic drugs, e.g. busulfan, bleomycin, within the past year. If prior therapy in lifetime, then excluded if history of pulmonary toxicities from administration. Patients who",0.85,2025-11-09T02:20:29.746530,cancer
NCT03423628,exc010,exclusion,condition,"[""general""]",condition,=,,,History or presence of myopathy or raised creatine kinase (CK) \>5 x upper limit of normal (ULN) on 2 occasions at screening.,0.85,2025-11-09T02:20:29.746530,cancer
NCT05736367,inc001,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,"* Have hormone receptor (HR) positive \[estrogen receptor( ER)+/progesterone receptor (PR)+, ER+/PR- or ER-/PR+)/Her2 negative breast cancer previously diagnosed by biopsy.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05736367,inc002,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,"Have early stage, clinical or anatomic stage I, II or III breast cancer (cT1cN0, cT1cN1, cT2N0, cT2N1, cT3N0)",0.85,2025-11-09T02:20:29.746530,cancer
NCT05736367,inc003,inclusion,condition,"[""general""]",condition,=,,,"Candidates for intended curative primary resection who have not had neoadjuvant therapy (endocrine/hormonal therapy, chemotherapy with or without immunotherapy).",0.85,2025-11-09T02:20:29.746530,cancer
NCT05736367,inc004,inclusion,condition,"[""general""]",condition,=,,,Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed surgical resection.,0.85,2025-11-09T02:20:29.746530,cancer
NCT05736367,exc001,exclusion,condition,"[""general""]",condition,=,,,"* Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating i",0.85,2025-11-09T02:20:29.746530,cancer
NCT05736367,exc002,exclusion,condition,"[""general""]",condition,=,,,Has triple negative (ER-/PR-/Her2-) or HER2+ breast cancer.,0.85,2025-11-09T02:20:29.746530,cancer
NCT05736367,exc003,exclusion,condition,"[""general""]",condition,=,,,Concomitant active malignancy,0.85,2025-11-09T02:20:29.746530,cancer
NCT05736367,exc004,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,"Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer)",0.85,2025-11-09T02:20:29.746530,cancer
NCT06053567,inc001,inclusion,demographic,"[""age""]",age,=,,,* Adult (age ≥ 18);,0.85,2025-11-09T02:20:29.746530,cancer
NCT06053567,inc002,inclusion,condition,"[""general""]",condition,=,,,High Anxiety Sensitivity (≥5 on the Short Scale Anxiety Sensitivity Index \[SSASI\]);,0.85,2025-11-09T02:20:29.746530,cancer
NCT06053567,inc003,inclusion,condition,"[""general""]",condition,=,,,"Daily smoker, ≥5 cigarettes (including e-cigarettes, little cigars/cigarillos) for ≥1 year;",0.85,2025-11-09T02:20:29.746530,cancer
NCT06053567,inc004,inclusion,condition,"[""general""]",condition,=,,,Motivated to quit smoking as evidenced by a score of ≥5 on a 0-10 Likert scale;,0.85,2025-11-09T02:20:29.746530,cancer
NCT06053567,inc005,inclusion,condition,"[""general""]",condition,=,,,Body mass index \&lt;40;,0.85,2025-11-09T02:20:29.746530,cancer
NCT06053567,inc006,inclusion,condition,"[""general""]",condition,=,,,Medical clearance to participate.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06053567,inc007,inclusion,condition,"[""general""]",condition,=,,,Located near a participating YMCA site (within 50 miles),0.85,2025-11-09T02:20:29.746530,cancer
NCT06053567,exc001,exclusion,condition,"[""general""]",condition,=,,,* Regular exercise defined as engaging in vigorous-intensity exercise for at least 75 minutes per week for the last 3 months,0.85,2025-11-09T02:20:29.746530,cancer
NCT06053567,exc002,exclusion,condition,"[""general""]",condition,=,,,Receiving current intervention for smoking cessation.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06053567,exc003,exclusion,condition,"[""general""]",condition,=,,,Outstanding debt to the YMCA,0.85,2025-11-09T02:20:29.746530,cancer
NCT06053567,exc004,exclusion,condition,"[""general""]",condition,=,,,Listed as a sex offender on the National Sex Offender Registry,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,inc001,inclusion,condition,"[""general""]",condition,=,,,* Histologically- or cytologically-documented advanced (Stage III not eligible for resection or curative radiation) or metastatic non-squamous NSCLC with specific mutations.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,inc002,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Documentation of locally assessed radiological disease progression while on or after last treatment based on Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,inc003,inclusion,condition,"[""general""]",condition,=,,,"Participants with genome mutations must have received 1 or 2 prior lines of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), including a third generation TKI for participants wit",0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,inc004,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Measurable disease per RECIST 1.1 as assessed by the local site investigator.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,inc005,inclusion,condition,"[""general""]",condition,=,,,"Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided",0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,inc006,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,inc007,inclusion,condition,"[""general""]",condition,=,,,"Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomiza",0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,inc008,inclusion,condition,"[""general""]",condition,=,,,Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,inc009,inclusion,condition,"[""general""]",condition,=,,,Have an ECOG performance status of 0 or 1 within 3 days before randomization.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,exc001,exclusion,condition,"[""general""]",condition,=,,,"include but are not limited to the following:

Inclusion Criteria:",0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,exc002,exclusion,condition,"[""general""]",condition,=,,,Histologically- or cytologically-documented advanced (Stage III not eligible for resection or curative radiation) or metastatic non-squamous NSCLC with specific mutations.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,exc003,exclusion,condition,"[""general""]",condition,=,,,Documentation of locally assessed radiological disease progression while on or after last treatment based on Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,exc004,exclusion,condition,"[""general""]",condition,=,,,"Participants with genome mutations must have received 1 or 2 prior lines of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), including a third generation TKI for participants wit",0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,exc005,exclusion,condition,"[""general""]",condition,=,,,Measurable disease per RECIST 1.1 as assessed by the local site investigator.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,exc006,exclusion,condition,"[""general""]",condition,=,,,"Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided",0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,exc007,exclusion,condition,"[""general""]",condition,=,,,Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,exc008,exclusion,condition,"[""general""]",condition,=,,,"Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomiza",0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,exc009,exclusion,condition,"[""general""]",condition,=,,,Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06074588,exc010,exclusion,condition,"[""general""]",condition,=,,,"Have an ECOG performance status of 0 or 1 within 3 days before randomization.

Exclusion Criteria:",0.85,2025-11-09T02:20:29.746530,cancer
NCT05775939,inc001,inclusion,condition,"[""general""]",condition,=,,,* Provide signed and dated informed consent form,0.85,2025-11-09T02:20:29.746530,cancer
NCT05775939,inc002,inclusion,condition,"[""general""]",condition,=,,,Willing to comply with all study procedures and be available for the duration of the study,0.85,2025-11-09T02:20:29.746530,cancer
NCT05775939,inc003,inclusion,demographic,"[""gender""]",gender,=,all,,"Male or female, aged \>= 18",0.85,2025-11-09T02:20:29.746530,cancer
NCT05775939,inc004,inclusion,condition,"[""general""]",condition,=,,,Life expectancy \>= 3 months as assessed by Radiation Oncologist,0.85,2025-11-09T02:20:29.746530,cancer
NCT05775939,inc005,inclusion,condition,"[""general""]",condition,=,,,Mean heart dose estimated by Radiation Oncologist to be \>= 5 Gy (physics dose or biologically equivalent dose),0.85,2025-11-09T02:20:29.746530,cancer
NCT05775939,inc006,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Pathologically proven (either histologic or cytologic) proven lung cancer or esophageal cancer,0.85,2025-11-09T02:20:29.746530,cancer
NCT05775939,inc007,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Planned radiation treatment course for management of lung or esophageal cancer \* Both standard and hypofractionation schedules are permitted,0.85,2025-11-09T02:20:29.746530,cancer
NCT05775939,exc001,exclusion,condition,"[""general""]",condition,=,,,* Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist,0.85,2025-11-09T02:20:29.746530,cancer
NCT05775939,exc002,exclusion,condition,"[""general""]",condition,=,,,Palliative radiation doses defined as 20 Gy in 5 fractions,0.85,2025-11-09T02:20:29.746530,cancer
NCT05304377,inc001,inclusion,condition,"[""general""]",condition,=,,,"* BCR-ABL1 positive CML in chronic phase, with or without T315I mutation.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05304377,inc002,inclusion,condition,"[""general""]",condition,=,,,"US: The patient has failed or is intolerant to at least one prior second-generation tyrosine kinase inhibitor (TKI) or asciminib. Rest of World: The patient has failed, is intolerant to, or not a cand",0.85,2025-11-09T02:20:29.746530,cancer
NCT05304377,inc003,inclusion,condition,"[""general""]",condition,=,,,ECOG performance status of 0 to 2.,0.85,2025-11-09T02:20:29.746530,cancer
NCT05304377,inc004,inclusion,condition,"[""general""]",condition,=,,,"Adequate hematologic, hepatic and renal function.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05304377,inc005,inclusion,condition,"[""general""]",condition,=,,,Prior bone marrow transplant allowed if ≥ 6 months prior to the first dose of ELVN-001.,0.85,2025-11-09T02:20:29.746530,cancer
NCT05304377,exc001,exclusion,condition,"[""general""]",condition,=,,,"* Treatment with anti-cancer or anti-CML therapy within 7 days or 5 half-lives, whichever is longer.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05304377,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"History of acute tyrosine kinase inhibitor (TKI)-related pancreatitis within 6 months of study entry. Active chronic pancreatitis, or pancreatic disease due to any cause.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05304377,exc003,exclusion,condition,"[""general""]",condition,=,,,QTc \>470 ms.,0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,inc001,inclusion,condition,"[""general""]",condition,=,,,3.1.1 Patients must have the following:,0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,inc002,inclusion,condition,"[""general""]",condition,=,,,Histologically confirmed muscle invasive urothelial cell carcinoma of the bladder (pT2 - pT4),0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,inc003,inclusion,condition,"[""general""]",condition,=,,,Eligible for standard cisplatin/gemcitabine chemotherapy as determined by the treating Medical Oncologist,0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,inc004,inclusion,condition,"[""general""]",condition,=,,,"1.2 Patients must have muscle-invasive urothelial cell carcinoma of the bladder (pT2 - pT4, N0-N1, M0,) as determined by bladder biopsy or trans-urethral resection of bladder tumor (TURBT) and staging",0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,inc005,inclusion,condition,"[""general""]",condition,=,,,1.3 Androgen receptor positivity by IHC within the nucleus of tumor cells (as determined by study Pathologist) is required to receive study treatment.,0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,inc006,inclusion,condition,"[""general""]",condition,=,,,1.4 Patients previously treated with intravesical therapy for non-muscle invasive urothelial carcinoma of the bladder are eligible for enrollment if the agent used was not gemcitabine or a platinum-co,0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,inc007,inclusion,demographic,"[""age""]",age,>=,18,years,"1.5 Age ≥18 years.

Because the safety and efficacy of Degarelix in pediatric patients have not been established, children (patients \<18 years of age) are excluded from this study.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,inc008,inclusion,condition,"[""general""]",condition,=,,,"1.6 ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).",0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,inc009,inclusion,condition,"[""general""]",condition,=,,,1.7 Patients must have adequate organ and marrow function as defined below:,0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,inc010,inclusion,condition,"[""general""]",condition,=,,,"absolute neutrophil count ≥1,000/mcL",0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,exc001,exclusion,condition,"[""general""]",condition,=,,,3.2.1 Patients who have previously received systemic or intravesical gemcitabine or platinum-containing chemotherapy,0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,exc002,exclusion,condition,"[""general""]",condition,=,,,"2.2 Patients taking testosterone, estrogen, or other sex hormone modifying agents are excluded from this study as these medications may interfere with the activity of the study drug, Degarelix.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,exc003,exclusion,condition,"[""general""]",condition,=,,,"2.3 Patients with uncontrolled intercurrent illness, as determined by the treating physician",0.85,2025-11-09T02:20:29.746530,cancer
NCT05839119,exc004,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,"2.4 Patients who are pregnant or breastfeeding. (The effects of Degarelix on the developing human fetus are unknown. However, ""based on findings in animal studies, \[Degarelix\] can cause fetal harm a",0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,inc001,inclusion,condition,"[""general""]",condition,=,,,"* Documented evidence of a pathogenic mutation at methionine-41 (M41) or neighboring splice site mutation (c.118-1, c.118-2) position in UBA1 mutation based on myeloid next-generation sequencing (NGS)",0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,inc002,inclusion,condition,"[""general""]",condition,=,,,"Current or documented evidence of past involvement within 6 months prior to enrollment of at least one of the following organ systems by VEXAS syndrome: cutaneous (e.g., neutrophilic dermatosis, cutan",0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,inc003,inclusion,condition,"[""general""]",condition,=,,,Receiving ongoing GC therapy (stable prednisone or prednisolone dose of 15-45 mg/day) leading up to enrollment. Note that patients who are stable on GC doses of 10-14 mg/day in addition to another non,0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,inc004,inclusion,condition,"[""general""]",condition,=,,,Karnofsky Performance Status ≥50%,0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,inc005,inclusion,condition,"[""general""]",condition,=,,,"Adequate organ function, meeting all the following criteria within 30 days prior to enrollment:",0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,inc006,inclusion,condition,"[""general""]",condition,=,,,Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN),0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,inc007,inclusion,condition,"[""general""]",condition,=,,,Total bilirubin ≤4 × ULN (≤8 × ULN in the setting of Gilbert's syndrome),0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,inc008,inclusion,labvalue,"[""test""]",value,=,,,Creatinine clearance (CrCl) ≥30 mL/min based on the Cockcroft-Gault formula,0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,inc009,inclusion,condition,"[""general""]",condition,=,,,Absolute neutrophil count ≥500/μL,0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,inc010,inclusion,condition,"[""general""]",condition,=,,,Prothrombin time (PT) or international normalized ratio (INR) ≤1.5 × ULN (unless prolonged due to therapeutic anticoagulation),0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,exc001,exclusion,condition,"[""general""]",condition,=,,,* Prior allogenic hematopoietic stem cell transplant (allo-HSCT) or solid organ transplant (other than corneal).,0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,exc002,exclusion,condition,"[""general""]",condition,=,,,"Current use of systemic GCs for conditions other than VEXAS syndrome, which, in the opinion of the Investigator, would interfere with adherence to a GC taper regimen and/or assessment of efficacy.",0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,exc003,exclusion,condition,"[""general""]",condition,=,,,More than one prior admission to an intensive care unit due to a VEXAS Syndrome flare within the prior 6 months.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,exc004,exclusion,condition,"[""general""]",condition,=,,,Received ≥9 units of intensive red blood cell (RBC) transfusions in the 90 days prior to enrollment.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,exc005,exclusion,condition,"[""general""]",condition,=,,,"Known concurrent myelodysplastic syndrome (MDS) requiring antineoplastic treatment, or allo-HSCT, or known high-risk or very high-risk MDS based on the Revised International Prognostic Scoring System ",0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,exc006,exclusion,condition,"[""general""]",condition,=,,,"Malignancy within 1 year prior to enrollment with the exception of MDS (per exclusion criterion), curatively treated non-melanoma skin cancer, or curatively treated carcinoma in situ. Patients with pr",0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,exc007,exclusion,condition,"[""general""]",condition,=,,,"Exposure to hypomethylating agents (HMA) within 6 months prior to enrollment, or exposure to more than 4 cycles of HMAs at any time.",0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,exc008,exclusion,condition,"[""general""]",condition,=,,,Exposure to non-GC anti-inflammatory therapy or hematologic support therapy within protocol defined timeframes prior to enrollment,0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,exc009,exclusion,condition,"[""general""]",condition,=,,,Exposure to anti-platelet therapy with the exception of low-dose aspirin (≤100 mg daily) within 28 days prior to enrollment.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06782373,exc010,exclusion,condition,"[""general""]",condition,=,,,"Known concomitant multiple myeloma, or serum M-protein ≥3 g/dL, involved-to uninvolved free light chain (FLC) ratio ≥100, or involved FLC level ≥100 mg/dL. Patients with MGUS may enroll.",0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,inc001,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,"* Participants must have suspected or confirmed clinically advanced stage (III-IV, defined as disease outside of the pelvis) ovarian, fallopian tube, or peritoneal cancer. If a patient has suspected o",0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,inc002,inclusion,condition,"[""general""]",condition,=,,,Participants must meet one of the following clinical categories:,0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,inc003,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Cohort 1: Patients with a new or suspected diagnosis of ovarian cancer who are deemed surgical candidates for primary cytoreductive surgery (as per their surgical gynecologic oncologist) and who have ,0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,inc004,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,"Cohort 2: Patients with newly diagnosed ovarian cancers who are being considered for either primary surgery or neoadjuvant chemotherapy by their surgical gynecologic oncologist, and who require a lapa",0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,inc005,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,"Cohort 3: Patients with recurrent ovarian cancer who are candidates for secondary cytoreduction, e.g. to confirm diagnosis of recurrent ovarian cancer and/or remove oligometastatic lesions.",0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,inc006,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Cohort 4: Patients with newly diagnosed ovarian cancers who have undergone neoadjuvant chemotherapy and are deemed surgical candidates for interval debulking surgery (as per their surgical gynecologic,0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,inc007,inclusion,demographic,"[""age""]",age,=,,,Participants must be 18 years of age or older.,0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,inc008,inclusion,condition,"[""general""]",condition,=,,,Patients must be deemed medically stable to undergo both percutaneous procedures and standard-of-care surgical procedures by their treating gynecologic oncologist and medical oncologist.,0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,inc009,inclusion,condition,"[""general""]",condition,=,,,Participants will undergo laboratory testing within 14 days\* prior to the microdevice placement.,0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,inc010,inclusion,condition,"[""general""]",condition,=,,,"Patients must have absolute neutrophil count ≥ 1,500/mcL",0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,exc001,exclusion,condition,"[""general""]",condition,=,,,"* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illne",0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,exc002,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Pregnant women are excluded from this study because of the possible increased dose of radiation from imaging associated with the microdevice placement and the potential risk to the pregnancy of the bi,0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,exc003,exclusion,condition,"[""general""]",condition,=,,,Uncorrectable bleeding or coagulation disorder known to cause increased risk with surgical or percutaneous biopsy procedures.,0.85,2025-11-09T02:20:29.746530,cancer
NCT04701645,exc004,exclusion,condition,"[""general""]",condition,=,,,"Significant risk factors (including, but not limited to, high risk of venous thrombosis, pulmonary embolism, stroke or myocardial infarction) precluding the safe cessation of anticoagulation medicatio",0.85,2025-11-09T02:20:29.746530,cancer
NCT05795595,inc001,inclusion,demographic,"[""age""]",age,>=,18,years,1. Age ≥18 years.,0.85,2025-11-09T02:20:29.746530,cancer
NCT05795595,inc002,inclusion,condition,"[""general""]",condition,=,,,"Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, and malignant pleural mesothelioma.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05795595,inc003,inclusion,condition,"[""general""]",condition,=,,,Eastern Cooperative Oncology Group performance status 0 or 1.,0.85,2025-11-09T02:20:29.746530,cancer
NCT05795595,inc004,inclusion,condition,"[""general""]",condition,=,,,"Adequate renal, liver, cardiac and pulmonary organ function.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05795595,inc005,inclusion,demographic,"[""gender""]",gender,=,all,,"Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX131 infusion.

Key",0.85,2025-11-09T02:20:29.746530,cancer
NCT05795595,exc001,exclusion,condition,"[""general""]",condition,=,,,1. Prior treatment with anti-CD70 targeting agents,0.85,2025-11-09T02:20:29.746530,cancer
NCT05795595,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"History of certain central nervous system (CNS), cardiac or pulmonary conditions.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05795595,exc003,exclusion,condition,"[""general""]",condition,=,,,"Presence of uncontrolled bacterial, viral, or fungal infection.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05795595,exc004,exclusion,condition,"[""general""]",condition,=,,,"Active HIV, hepatitis B virus or hepatitis C virus infection.",0.85,2025-11-09T02:20:29.746530,cancer
NCT05795595,exc005,exclusion,condition,"[""general""]",condition,=,,,Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.,0.85,2025-11-09T02:20:29.746530,cancer
NCT05795595,exc006,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Women who are pregnant or breastfeeding.,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,inc001,inclusion,demographic,"[""age""]",age,>=,18,years,* Male or female and ≥ 18 years of age,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,inc002,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Histologically and/or cytologically confirmed primary diagnosis of R/M HNSCC,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,inc003,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,Participants with oropharyngeal cancer will be required to have proof of p16 negative status submitted on the basis of a pathology report,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,inc004,inclusion,condition,"[""general""]",condition,=,,,"At least 1 measurable lesion by contrast CT or MRI scan according to RECIST v.1.1. Such lesions must not have been previously irradiated; if the measurable lesion(s) has been irradiated, clear progres",0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,inc005,inclusion,condition,"[""diagnosis"", ""cancer""]",diagnosis,=,cancer,,"Participants must have failed prior therapy with an anti-PD-1/PD-L1 ICI and with platinum-based chemotherapy administered in combination or sequentially, in either the locally advanced or R/M setting.",0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,inc006,inclusion,condition,"[""general""]",condition,=,,,Patient's tumor must be considered inoperable and incurable,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,inc007,inclusion,condition,"[""general""]",condition,=,,,Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with a life expectancy of at least 12 weeks,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,inc008,inclusion,condition,"[""general""]",condition,=,,,"For women of childbearing potential (WOCBP), documentation of negative serum pregnancy test within 30 days of randomization",0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,inc009,inclusion,demographic,"[""gender""]",gender,=,male,,"For WOCBP and male participants whose sexual partners are of childbearing potential, agreement to use an effective method of contraception during the study and for at least 5 months after the last dos",0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,inc010,inclusion,condition,"[""general""]",condition,=,,,Ability to give written informed consent and comply with protocol requirements,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,exc001,exclusion,condition,"[""general""]",condition,=,,,* Participants who have received \> 2 prior lines of anticancer therapy or prior treatment with cetuximab/alternative EGFR inhibitors for the treatment of R/M HNSCC,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent or cetuximab,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,exc003,exclusion,condition,"[""general""]",condition,=,,,Known or suspected untreated and uncontrolled brain metastases or leptomeningeal carcinomatosis Note: Participants with locally treated brain metastases are eligible provided 2 weeks have elapsed sinc,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,exc004,exclusion,condition,"[""general""]",condition,=,,,Prior treatment with any other investigational drug or biologic agent or radiation therapy before a washout has been completed (must be completed prior to randomization):,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,exc005,exclusion,condition,"[""general""]",condition,=,,,"2 weeks (14 days) or 5 half-lives, whichever is shorter, for chemotherapeutic agents, small molecules, and checkpoint inhibitors",0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,exc006,exclusion,condition,"[""general""]",condition,=,,,"3 weeks (21 days) or 5 half-lives, whichever is shorter, for antibody-drug conjugates",0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,exc007,exclusion,condition,"[""general""]",condition,=,,,4 weeks (28 days) for cell therapies,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,exc008,exclusion,condition,"[""general""]",condition,=,,,2 weeks (14 days) for radiation therapy,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,exc009,exclusion,condition,"[""general""]",condition,=,,,Any unresolved and significant toxicity (National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] version 5.0) Grade \> 2 from previous anticancer therapy (including radi,0.85,2025-11-09T02:20:29.746530,cancer
NCT06064877,exc010,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Significant cardiovascular disease, including: Cardiac failure New York Heart Association class III or IV; Myocardial infarction, severe or unstable angina within 6 months prior to randomization; Hist",0.85,2025-11-09T02:20:29.746530,cancer
NCT02325674,inc001,inclusion,condition,"[""general""]",condition,=,,,* Patients treated with metreleptin through commercial supply at the time or before enrolment into registry,0.85,2025-11-09T02:20:29.746530,diabetes
NCT02325674,inc002,inclusion,condition,"[""general""]",condition,=,,,Patients who provide a written consent,0.85,2025-11-09T02:20:29.746530,diabetes
NCT02325674,inc003,inclusion,condition,"[""general""]",condition,=,,,Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply,0.85,2025-11-09T02:20:29.746530,diabetes
NCT02325674,exc001,exclusion,condition,"[""general""]",condition,=,,,• Patients currently treated with an investigational agent as part of a clinical trial,0.85,2025-11-09T02:20:29.746530,diabetes
NCT05893927,inc001,inclusion,demographic,"[""age""]",age,>=,18,years,* Age ≥ 18 years,0.85,2025-11-09T02:20:29.746530,diabetes
NCT05893927,inc002,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,Diagnosis of Type 2 Diabetes with HA1c \>8.0,0.85,2025-11-09T02:20:29.746530,diabetes
NCT05893927,inc003,inclusion,condition,"[""general""]",condition,=,,,"Current patients of the Family Healthcare Center, Reading Hospital Tower health.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT05893927,exc001,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,* Identified special populations (pregnancy or individuals currently incarcerated),0.85,2025-11-09T02:20:29.746530,diabetes
NCT05893927,exc002,exclusion,condition,"[""general""]",condition,=,,,Patients without access to their own smart phone,0.85,2025-11-09T02:20:29.746530,diabetes
NCT05893927,exc003,exclusion,condition,"[""general""]",condition,=,,,Any patient who is unable to provide their own informed consent to participate in the study,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,inc001,inclusion,condition,"[""general""]",condition,=,,,1. Capable of giving and has provided a signed Informed Consent Form (ICF).,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,inc002,inclusion,demographic,"[""age""]",age,=,,,"Male or female age 18 to 75 years inclusive, at the time of signing the informed consent.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,inc003,inclusion,demographic,"[""gender""]",gender,=,male,,Women of childbearing potential (WOCBP) and male subjects who are partners of WOCBP must agree to use an acceptable form of contraception during the study and for 30 days following the last dose of st,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,inc004,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,Clinical diagnosis of type 2 diabetes as per guidelines.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,inc005,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,"Clinical diagnosis of diabetic kidney disease in the opinion of the principal investigator, or renal biopsy proven diabetic kidney disease without evidence of additional pathologic findings of alterna",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,inc006,inclusion,condition,"[""general""]",condition,=,,,"At screening, based on two 24-hour urine collections, geometric mean of two urinary albumin creatine ratios (UACR) ≥ 400 mg/g and ≤ 3500 mg/g.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,inc007,inclusion,condition,"[""general""]",condition,=,,,"At screening, eGFR equal or greater than 30 and less than 90 mL/min/1.73 m\^2.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,inc008,inclusion,condition,"[""general""]",condition,=,,,Body mass index (BMI) ≤ 40.0 kg/m\^2.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,inc009,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,If on diabetes and anti-hypertensive medications:,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,inc010,inclusion,condition,"[""general""]",condition,=,,,Angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) inhibitors dose must be stable for 3 months before screening.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,exc001,exclusion,condition,"[""general""]",condition,=,,,1. Has a solitary kidney.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,exc002,exclusion,condition,"[""general""]",condition,=,,,Has a positive drug screen.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,exc003,exclusion,condition,"[""general""]",condition,=,,,Known kidney disease other than diabetic kidney disease.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,exc004,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"End stage renal disease (ESRD) (i.e., peritoneal dialysis, hemodialysis, or history of kidney transplantation).",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,exc005,exclusion,condition,"[""general""]",condition,=,,,Acute kidney injury or dialysis within the last 3 months before the screening visit.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,exc006,exclusion,condition,"[""general""]",condition,=,,,Uncontrolled diabetes as defined by HbA1c \>10 at screening.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,exc007,exclusion,condition,"[""general""]",condition,=,,,Uncontrolled hypertension with systolic blood pressure (SBP) \>140 mmHg or diastolic blood pressure (DBP) \>90 mmHg during screening.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,exc008,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Unstable cardiovascular disease or history of myocardial infarction or arterial thromboembolic events within 3 months prior to screening or severe or unstable angina, New York Heart Association (NYHA)",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,exc009,exclusion,condition,"[""general""]",condition,=,,,Patients on IV medication containing cyclodextrin.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06489340,exc010,exclusion,condition,"[""general""]",condition,=,,,"Patients on steroids, except for those on low-dose topical steroids (per PI discretion) or intranasal or inhaled steroids.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,inc001,inclusion,demographic,"[""age""]",age,>,18,years,* Age \>18 years,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,inc002,inclusion,condition,"[""general""]",condition,=,,,Good general health,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,inc003,inclusion,condition,"[""general""]",condition,=,,,Fasting C-peptide concentration \<0.7 ng/ml,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,inc004,inclusion,labvalue,"[""test"", ""HbA1c""]",value,=,,,Poor glycemic control (HbA1c=7.0-11.0%),0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,inc005,inclusion,condition,"[""general""]",condition,=,,,Treatment with multiple daily insulin injections or insulin pump,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,inc006,inclusion,condition,"[""general""]",condition,=,,,Total daily insulin dose ≥0.6 U/kg per day,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,inc007,inclusion,condition,"[""general""]",condition,=,,,Stable insulin dose (±4 units) in the preceding three months.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,inc008,inclusion,condition,"[""general""]",condition,=,,,eGFR≥60 ml/min,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,inc009,inclusion,condition,"[""general""]",condition,=,,,Weight stable over the preceding 3 months (± 3 pounds),0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,inc010,inclusion,condition,"[""general""]",condition,=,,,Do not participate in an excessively heavy exercise program,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,exc001,exclusion,condition,"[""general""]",condition,=,,,Daily insulin dose \<0.6 U/kg per day,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,exc002,exclusion,condition,"[""general""]",condition,=,,,Fasting C-peptide \>0.7 ng/ml,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,exc003,exclusion,condition,"[""general""]",condition,=,,,HbA1c \<7.0% or \>11.0%,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,exc004,exclusion,condition,"[""general""]",condition,=,,,eGFR\<60 ml/min,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,exc005,exclusion,condition,"[""general""]",condition,=,,,Hematuria in urine analysis,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,exc006,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,"Pregnancy, lactating, positive pregnancy test or planning to become pregnant in the following year.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,exc007,exclusion,condition,"[""general""]",condition,=,,,Women of child-bearing potential will be requested to use at least two barrier methods before being enrolled in the study.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,exc008,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,Major organ system disease which includes: (i) malignancy or history of malignancy including bladder cancer; (ii) Congestive heart failure or history of coronary heart disease or any other cardiac dis,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,exc009,exclusion,condition,"[""general""]",condition,=,,,Evidence of proliferative diabetic retinopathy,0.85,2025-11-09T02:20:29.746530,diabetes
NCT03878459,exc010,exclusion,condition,"[""general""]",condition,=,,,Patients enrolled in a heavy exercise program,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,inc001,inclusion,condition,"[""general""]",condition,=,,,Part 1 (Imaging Optimization):,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,inc002,inclusion,condition,"[""general""]",condition,=,,,Able and willing to sign informed consent.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,inc003,inclusion,demographic,"[""age""]",age,>=,18,years,"Age \>= 18 years old at the time of study entry.

Part 2 (Pilot Study):",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,inc004,inclusion,condition,"[""general""]",condition,=,,,Group 1 (Fatty Liver Patients without NASH):,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,inc005,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,NAFL as determined by either clinical suspicion of fatty liver disease based on:,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,inc006,inclusion,condition,"[""general""]",condition,=,,,"steatosis by imaging or histology,",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,inc007,inclusion,condition,"[""general""]",condition,=,,,"no significant alcohol consumption,",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,inc008,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,"absence of coexisting liver disease OR NAFL determined by liver biopsy 3 months prior to the scan, with the presence of fat on histology but absent ballooning or fibrosis. (nonalcoholic steatohepatiti",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,inc009,inclusion,condition,"[""general""]",condition,=,,,Able and willing to sign informed consent.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,inc010,inclusion,demographic,"[""age""]",age,>=,18,years,Age ≥ 18 years old at the time of study entry.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,exc001,exclusion,condition,"[""general""]",condition,=,,,Part 1 (Imaging Optimization): For Cohorts 1/B only:,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,exc002,exclusion,condition,"[""general""]",condition,=,,,"Poorly controlled hypertension, with blood pressure at study entry \> 160 mmHg systolic or \> 100 mmHg diastolic.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,exc003,exclusion,condition,"[""general""]",condition,=,,,Congestive heart failure with New York Heart Association (NYHA) status ≥ 2.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,exc004,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Pregnant or nursing.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,exc005,exclusion,condition,"[""general""]",condition,=,,,"Participants unwilling or unable to undergo magnetic resonance (MR) imaging, including participants with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular c",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,exc006,exclusion,condition,"[""general""]",condition,=,,,"Participant size too large to fit in MR scanner.

Part 2 (Pilot Study): All groups",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,exc007,exclusion,condition,"[""general""]",condition,=,,,"Poorly controlled hypertension, with blood pressure at study entry \> 160 mmHg systolic or \> 100 mmHg diastolic.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,exc008,exclusion,condition,"[""general""]",condition,=,,,Current treatment with oral medication for diabetes.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,exc009,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Pregnant or nursing.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06176079,exc010,exclusion,condition,"[""general""]",condition,=,,,"Participants unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT04615546,inc001,inclusion,demographic,"[""age""]",age,between,"18,70",years,* Male or female patients 18-70 years of age,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04615546,inc002,inclusion,condition,"[""general""]",condition,=,,,Post-bariatric surgery more than 6 months prior to signing the informed consent (not required for non-surgical controls),0.85,2025-11-09T02:20:29.746530,diabetes
NCT04615546,inc003,inclusion,condition,"[""general""]",condition,=,,,Documented history of hyperinsulinemic hypoglycemia (not required for post-bariatric and non-surgical controls),0.85,2025-11-09T02:20:29.746530,diabetes
NCT04615546,exc001,exclusion,condition,"[""general""]",condition,=,,,* Patients currently using sulfonylureas or other medications that may interfere with glucose metabolism within 5 half-lives of drug.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04615546,exc002,exclusion,condition,"[""general""]",condition,=,,,Participation in any clinical investigation within 4 weeks prior to dosing,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04615546,exc003,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of or current insulinoma,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04615546,exc004,exclusion,condition,"[""general""]",condition,=,,,Active infection or significant acute illness within 2 weeks prior to dosing,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04615546,exc005,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Female patients who are pregnant or lactating,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04615546,exc006,exclusion,condition,"[""general""]",condition,=,,,Women of childbearing potential and not utilizing effective contraceptive methods,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04615546,exc007,exclusion,condition,"[""general""]",condition,=,,,"Inadequate end organ function as defined by: Serum creatinine \>2.0 mg/dL, alanine transaminase (ALT) and aspartate aminotransferase (AST) \> 2 x Upper Normal Limit",0.85,2025-11-09T02:20:29.746530,diabetes
NCT04615546,exc008,exclusion,condition,"[""general""]",condition,=,,,Allergy to test meal or medications used in the study,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04754269,inc001,inclusion,condition,"[""general""]",condition,=,,,* Parent identifies child as Latino/a/x,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04754269,inc002,inclusion,demographic,"[""age""]",age,=,,,Child age 1 to 5 (12 to 59 months),0.85,2025-11-09T02:20:29.746530,diabetes
NCT04754269,inc003,inclusion,condition,"[""general""]",condition,=,,,Parent has a cell phone that can receive text messages,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04754269,inc004,inclusion,condition,"[""general""]",condition,=,,,Parent speak English or Spanish,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04754269,exc001,exclusion,condition,"[""general""]",condition,=,,,• Child does not feed by mouth,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,inc001,inclusion,condition,"[""general""]",condition,=,,,* Adults aged 18 to 60 years,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,inc002,inclusion,condition,"[""general""]",condition,=,,,Residents of Massachusetts,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,inc003,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,Diagnosed with prediabetes,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,inc004,inclusion,condition,"[""general""]",condition,=,,,Body Mass Index (BMI) greater than 27 kg/m²,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,inc005,inclusion,condition,"[""general""]",condition,=,,,Otherwise healthy,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,inc006,inclusion,condition,"[""general""]",condition,=,,,Not pregnant,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,inc007,inclusion,condition,"[""general""]",condition,=,,,Willing to take a nutritional supplement,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,exc001,exclusion,condition,"[""general""]",condition,=,,,"* Use of any medications for diabetes, dyslipidemia, or immunosuppression",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,exc002,exclusion,condition,"[""general""]",condition,=,,,Current use of any supplements containing n-3 fatty acids,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,exc003,exclusion,condition,"[""general""]",condition,=,,,"Current use of tobacco/nicotine products, marijuana, or illicit drugs",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,exc004,exclusion,condition,"[""general""]",condition,=,,,"Self-reported consumption of a diet rich in plant- or marine-derived fats (e.g., fatty fish, nuts, seeds, or olive oil)",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,exc005,exclusion,condition,"[""general""]",condition,=,,,Use of hormone therapy (except oral contraceptives),0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,exc006,exclusion,condition,"[""general""]",condition,=,,,"Known allergies to fish, seafood, or any fish-derived products, including bottarga",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,exc007,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Clinical evidence or history of cardiac, pulmonary, hepatic, or renal insufficiency",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,exc008,exclusion,condition,"[""general""]",condition,=,,,Immunodeficiency conditions,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,exc009,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of non-skin cancer,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06988462,exc010,exclusion,condition,"[""general""]",condition,=,,,Participation in other clinical research studies,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,inc001,inclusion,condition,"[""general""]",condition,=,,,"* Men and women, aged 18-65 years",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,inc002,inclusion,condition,"[""general""]",condition,=,,,Body mass index of 30-45 kg/m2,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,inc003,inclusion,condition,"[""general""]",condition,=,,,Able to understand written and spoken English and/or Spanish,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,inc004,inclusion,condition,"[""general""]",condition,=,,,Fasting hyperinsulinemia (fasting serum insulin ≥ 13 μU/mL),0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,inc005,inclusion,condition,"[""general""]",condition,=,,,Completion of the graded insulin suppression test (GIST) protocol (Group H),0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,inc006,inclusion,condition,"[""general""]",condition,=,,,"Written informed consent (in English or Spanish) and any locally required authorization (e.g., Health Insurance Portability and Accountability Act) obtained from the participant prior to performing an",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,exc001,exclusion,condition,"[""general""]",condition,=,,,* Unable to provide informed consent in English or Spanish,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,exc002,exclusion,condition,"[""general""]",condition,=,,,Documented weight loss of ≥ 5% of baseline within the previous 3 months,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,exc003,exclusion,condition,"[""general""]",condition,=,,,"Abnormal blood pressure (including on treatment, if prescribed): Systolic blood pressure \< 90 mm Hg or \> 160 mm Hg, and/or Diastolic blood pressure \< 60 mm Hg or \> 100 mm Hg",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,exc004,exclusion,condition,"[""general""]",condition,=,,,Abnormal resting heart rate: \< 60 or ≥ 110 bpm,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,exc005,exclusion,condition,"[""general""]",condition,=,,,Sinus brady- or tachycardia that has been worked up and considered benign by the recruit's personal physician may be permitted at the PI's discretion,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,exc006,exclusion,condition,"[""general""]",condition,=,,,"Abnormal screening electrocardiogram on GIST screening (or if on file, performed within previous 90 d):",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,exc007,exclusion,condition,"[""general""]",condition,=,,,Non-sinus rhythm,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,exc008,exclusion,condition,"[""general""]",condition,=,,,Heart conduction blocks,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,exc009,exclusion,condition,"[""general""]",condition,=,,,Previously unknown ischaemic changes that persist on repeat EKG:,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06606327,exc010,exclusion,condition,"[""general""]",condition,=,,,ST elevations,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,inc001,inclusion,demographic,"[""age""]",age,=,,,1. Age 18 or older and able to provide informed consent.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,inc002,inclusion,condition,"[""general""]",condition,=,,,"Has an open wound or ulceration, preferably with tunneling or undermining.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,inc003,inclusion,condition,"[""general""]",condition,=,,,"If multiple wounds/ulcerations are present, only one will be selected for Miro3D treatment.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,inc004,inclusion,condition,"[""general""]",condition,=,,,Other wounds must be ≥2 cm away from the study wound.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,inc005,inclusion,condition,"[""general""]",condition,=,,,"Wound should be debrided with a clinical goal of healing, even if some infection remains.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,inc006,inclusion,condition,"[""general""]",condition,=,,,Previous infections must be adequately treated and controlled (per IDSA guidelines).,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,inc007,inclusion,condition,"[""general""]",condition,=,,,Willing and able to comply with offloading and/or compression requirements.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,inc008,inclusion,condition,"[""general""]",condition,=,,,Must have a stable living environment for wound care adherence.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,inc009,inclusion,condition,"[""general""]",condition,=,,,Study wound must have a clean base free of devitalized tissue or debris at the time of Miro3D placement.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,inc010,inclusion,condition,"[""general""]",condition,=,,,Provides consent for digital photo documentation.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,exc001,exclusion,condition,"[""general""]",condition,=,,,"1. Active, untreated osteomyelitis.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,exc002,exclusion,condition,"[""general""]",condition,=,,,Malignancy or vasculitis at the wound site.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,exc003,exclusion,condition,"[""general""]",condition,=,,,Undergoing chemotherapy.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,exc004,exclusion,condition,"[""general""]",condition,=,,,On dialysis.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,exc005,exclusion,condition,"[""general""]",condition,=,,,Use of investigational drugs or therapies within 30 days before screening.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,exc006,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,Conditions that significantly impair study adherence or known history of medical non-compliance.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,exc007,exclusion,condition,"[""general""]",condition,=,,,Known sensitivity to porcine materials.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,exc008,exclusion,condition,"[""general""]",condition,=,,,Third-degree burns.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,exc009,exclusion,condition,"[""general""]",condition,=,,,Worsening ischemia or gangrene at screening.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06939673,exc010,exclusion,condition,"[""general""]",condition,=,,,Prior radiation to the study wound site.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,inc001,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,1. Diagnosed with type 2 diabetes,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,inc002,inclusion,demographic,"[""age""]",age,=,,,Age 18 to 65,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,inc003,inclusion,labvalue,"[""test""]",value,=,,,Hemoglobin A1c (blood draw or point-of-care) test available within the last 3 months,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,inc004,inclusion,labvalue,"[""test""]",value,=,,,Most recent hemoglobin A1c result between 8.0 and 11.0,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,inc005,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,Currently receiving treatment for diabetes by a licensed healthcare provider.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,inc006,inclusion,condition,"[""general""]",condition,=,,,Reliable access to a personal smart phone that is compatible with CGM,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,inc007,inclusion,condition,"[""general""]",condition,=,,,English speaking,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,exc001,exclusion,condition,"[""general""]",condition,=,,,1. Type 1 diabetes,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,exc002,exclusion,condition,"[""general""]",condition,=,,,"Secondary type 2 diabetes (diagnosis secondary to other medical conditions such as pancreatitis, Cystic Fibrosis, or Cushing disease)",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,exc003,exclusion,condition,"[""general""]",condition,=,,,Prescribed short-acting (mealtime) insulin as part of diabetes treatment plan,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,exc004,exclusion,condition,"[""general""]",condition,=,,,Known or acknowledged active substance use disorder or that would interfere or negatively impact participation in the study,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06374186,exc005,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Diagnosis of a medical/psychiatric condition that would prevent participation in the study (e.g., Intellectual Disability, Alzheimer's disease, Traumatic Brain Injury, Schizophrenia)",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,inc001,inclusion,condition,"[""general""]",condition,=,,,* 30-65 years old inclusive,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,inc002,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,"Diagnosis with type 1 diabetes (T1D) or other insulin deficiency diabetes (latent autoimmune disease of adulthood, diabetes secondary to pancreatitis)",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,inc003,inclusion,condition,"[""general""]",condition,=,,,Less than 1.0 exercise sessions per week,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,inc004,inclusion,condition,"[""general""]",condition,=,,,Smartphone ownership,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,inc005,inclusion,condition,"[""general""]",condition,=,,,English literacy,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,inc006,inclusion,condition,"[""general""]",condition,=,,,Under regular care by a healthcare provider (1+ appointments per year),0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,inc007,inclusion,condition,"[""general""]",condition,=,,,Home Broadband wireless Internet or cell phone network,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,inc008,inclusion,labvalue,"[""test""]",value,=,,,Using continuous glucose monitor (CGM) and sharing data with medical record for at least 6 weeks,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,inc009,inclusion,condition,"[""general""]",condition,=,,,Using insulin pump or pen and sharing data with medical record for at least 6 weeks,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,exc001,exclusion,condition,"[""general""]",condition,=,,,* Diabetic ketoacidosis not clearly related to pump site failure in past 6 months,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,exc002,exclusion,condition,"[""general""]",condition,=,,,\>1 episode of severe hypoglycemia (altered mental and/or physical status requiring assistance from another person for recovery) in past 6 months,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,exc003,exclusion,condition,"[""general""]",condition,=,,,Resting blood pressure \>160mmHg systolic or \>100 mmHg diastolic.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,exc004,exclusion,condition,"[""general""]",condition,=,,,Myocardial infarction or angina in past 12 months,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,exc005,exclusion,condition,"[""general""]",condition,=,,,"Uncontrolled arrhythmia (e.g., atrial fibrillation with rapid ventricular response, new onset atrial fibrillation, ventricular tachycardia, escape rhythms)",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,exc006,exclusion,condition,"[""general""]",condition,=,,,Congestive heart failure (stage 3 or 4),0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,exc007,exclusion,condition,"[""general""]",condition,=,,,Exercise-induced asthma (not controlled on inhalers),0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,exc008,exclusion,condition,"[""general""]",condition,=,,,Chronic obstructive pulmonary disease (requiring home oxygen),0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,exc009,exclusion,condition,"[""general""]",condition,=,,,Renal failure,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06967701,exc010,exclusion,condition,"[""general""]",condition,=,,,Cognitive impairment,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,inc001,inclusion,demographic,"[""age""]",age,between,"18,45",years,* Age 18-45 years,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,inc002,inclusion,labvalue,"[""test""]",value,=,,,HbA1C \<6.5%,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,inc003,inclusion,condition,"[""general""]",condition,=,,,Normal weight individuals: BMI 17-25 kg/m\^2,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,inc004,inclusion,condition,"[""general""]",condition,=,,,Obese individuals: BMI \>30 kg/m\^2,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,exc001,exclusion,condition,"[""general""]",condition,=,,,* Creatinine \>1.5mg/dL,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,exc002,exclusion,condition,"[""general""]",condition,=,,,Hematocrit \<35% for females and \<39% for males,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,exc003,exclusion,condition,"[""general""]",condition,=,,,ALT and AST \>2.5X upper limit of normal,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,exc004,exclusion,condition,"[""general""]",condition,=,,,Abnormal TSH,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,exc005,exclusion,condition,"[""general""]",condition,=,,,Abnormal PT/PTT/INR,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,exc006,exclusion,condition,"[""general""]",condition,=,,,Triglycerides \>200 mg/dL,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,exc007,exclusion,condition,"[""general""]",condition,=,,,"Known hepatic, gastrointestinal, renal, neurologic, psychiatric, cerebrovascular disease",0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,exc008,exclusion,condition,"[""general""]",condition,=,,,Uncontrolled hypertension,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,exc009,exclusion,condition,"[""general""]",condition,=,,,Current or past 3 months use of ketogenic diet,0.85,2025-11-09T02:20:29.746530,diabetes
NCT04328337,exc010,exclusion,condition,"[""general""]",condition,=,,,"Use of any medications, vitamins, or supplements that can alter cerebral metabolism or lipids",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06908057,inc001,inclusion,condition,"[""general""]",condition,=,,,1. Able to provide informed consent (adults 18 and above) and assent if seven or above. Legally authorized representative (LAR) is able to provide consent in case of minors or in case of adults unable,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06908057,inc002,inclusion,condition,"[""diagnosis"", ""diabetes""]",diagnosis,=,diabetes,,"Children \> 2 years and adults at elevated risk of developing (or having misdiagnosed) clinically evident Stage 3 T1D because they have at least one of the following:

   i. have one or more first- or",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06908057,inc003,inclusion,condition,"[""general""]",condition,=,,,"Resides in the following Counties: Orange, Seminole, Osceola, Lake, Volusia, Brevard, Polk, Hillsborough.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06908057,exc001,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,1. People with a diagnosis of type stage 3T1D or T1D clinical definition per ADA Standards of Care,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06908057,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of organ transplant,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06908057,exc003,exclusion,condition,"[""general""]",condition,=,,,Be deemed unable or unlikely to comply with the protocol.,0.85,2025-11-09T02:20:29.746530,diabetes
NCT06908057,exc004,exclusion,condition,"[""general""]",condition,=,,,"Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete study visit/s.",0.85,2025-11-09T02:20:29.746530,diabetes
NCT06835283,inc001,inclusion,condition,"[""general""]",condition,=,,,1. veteran between the ages of 60 to 85,0.85,2025-11-09T02:20:29.746530,dementia
NCT06835283,inc002,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,clinical diagnosis of mild to moderate Alzheimer's disease or related dementia,0.85,2025-11-09T02:20:29.746530,dementia
NCT06835283,inc003,inclusion,condition,"[""general""]",condition,=,,,clinically significant neuropsychiatric symptoms (NPS) evidenced by a score ≥ 2 in at least one domain of the Neuropsychiatric Inventory Questionnaire,0.85,2025-11-09T02:20:29.746530,dementia
NCT06835283,inc004,inclusion,condition,"[""general""]",condition,=,,,mild to moderate cognitive impairment demonstrated by a Mini-Mental State Examination (MMSE) score of 15-23,0.85,2025-11-09T02:20:29.746530,dementia
NCT06835283,inc005,inclusion,condition,"[""general""]",condition,=,,,"have a caregiver who is able and willing to escort the patient to/from clinic visits, answer questionnaires, and assist in the implementation of treatment sessions at home",0.85,2025-11-09T02:20:29.746530,dementia
NCT06835283,inc006,inclusion,condition,"[""general""]",condition,=,,,"if taking psychotropic medications, demonstrate stability for at least 4 weeks of treatment",0.85,2025-11-09T02:20:29.746530,dementia
NCT06835283,exc001,exclusion,condition,"[""general""]",condition,=,,,1. any contraindication for MRI,0.85,2025-11-09T02:20:29.746530,dementia
NCT06835283,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"any contraindication for iTBS/tDCS including but not limited to seizure disorder, severe cardiovascular disease, history of brain surgery, or stroke involving the cerebral cortex near area of stimulat",0.85,2025-11-09T02:20:29.746530,dementia
NCT06835283,exc003,exclusion,condition,"[""general""]",condition,=,,,current alcohol or substance use disorder determined by QuickSCID (nicotine allowed; mild cannabis and alcohol use is allowed),0.85,2025-11-09T02:20:29.746530,dementia
NCT06835283,exc004,exclusion,condition,"[""general""]",condition,=,,,"neuropsychiatric symptoms (NPS) that are severe enough to preclude the intervention from being delivered safely and effectively, particularly agitation or aggression.

6\) any unstable coexisting medi",0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,inc001,inclusion,condition,"[""general""]",condition,=,,,"1. Active duty uniformed SM or Veteran who is currently eligible for treatment at WRNMMC (i.e., Defense Enrollment Eligibility Reporting System (DEERS)-eligible).",0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,inc002,inclusion,condition,"[""general""]",condition,=,,,"Ability to read, write, and speak English.",0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,inc003,inclusion,condition,"[""general""]",condition,=,,,Ability to provide informed consent.,0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,inc004,inclusion,condition,"[""general""]",condition,=,,,NICoE Intensive Outpatient Program (IOP) or NatHx Study comprehensive evaluation ≥3 years prior to current evaluation with valid neuropsychological test results.,0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,inc005,inclusion,condition,"[""general""]",condition,=,,,Consent to allow access to prior research data collected through the NICoE TBI Neuroimaging Core Project or NatHx Study and consent to allow access to at least 1 prior blood specimen previously collec,0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,inc006,inclusion,condition,"[""general""]",condition,=,,,Loss of consciousness (LOC) or post-traumatic amnesia (PTA),0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,inc007,inclusion,condition,"[""general""]",condition,=,,,Alteration of consciousness (AOC),0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,inc008,inclusion,condition,"[""general""]",condition,=,,,Evidence of neurologic dysfunction,0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,inc009,inclusion,condition,"[""general""]",condition,=,,,TBI-related abnormality on structural neuroimaging (either CT or MRI). Additional Healthy Control Criteria,0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,inc010,inclusion,condition,"[""general""]",condition,=,,,History of military deployment.,0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,exc001,exclusion,condition,"[""general""]",condition,=,,,"1. Disabling neurologic or psychological disorders such as autism, cerebral palsy, developmental disorder, stroke, brain tumor, multiple sclerosis, meningitis, encephalitis, brain abscess, vascular ma",0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,exc002,exclusion,condition,"[""general""]",condition,=,,,Diabetes mellitus requiring drug treatment,0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,exc003,exclusion,condition,"[""general""]",condition,=,,,Hypertension requiring more than 1 antihypertensive drug to control BP,0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,exc004,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of myocardial infarction or other systemic vasculopathies,0.85,2025-11-09T02:20:29.746530,dementia
NCT06034509,exc005,exclusion,condition,"[""general""]",condition,=,,,Dementia diagnosis at initial NICoE/NatHx Study assessment,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,inc001,inclusion,demographic,"[""age""]",age,>=,55,years,1. Age ≥ 55 years;,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,inc002,inclusion,condition,"[""general""]",condition,=,,,Independent in activities of daily living and without clinically significant cognitive impairment as determined by a mini-mental status examination (MMSE) score ≥ 26;,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,inc003,inclusion,condition,"[""general""]",condition,=,,,"Due to the effect of reproductive hormones on autonomic regulation, sleep and cognition, women will be postmenopausal;",0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,inc004,inclusion,condition,"[""general""]",condition,=,,,time spent in bed not greater than 8.5 hours;,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,inc005,inclusion,condition,"[""general""]",condition,=,,,"Sedentary, defined as participation in exercise of moderate intensity for less than 30 minutes per day and less than two times per week on a regular basis.",0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,inc006,inclusion,condition,"[""general""]",condition,=,,,"average daily light exposure indicative of indoor environments (from questionnaire).

Inclusion criteria for the insomnia group:",0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,inc007,inclusion,condition,"[""general""]",condition,=,,,Meet criteria for chronic insomnia disorder according to the International Classification of Sleep Disorders (3rd Ed.);,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,inc008,inclusion,condition,"[""general""]",condition,=,,,Subjective sleep efficiency less than 80% and/or awakening earlier than desired if before 6 AM for ≥3 nights/week in the previous 4 weeks;,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,inc009,inclusion,condition,"[""general""]",condition,=,,,Subjective WASO (sWASO) ≥ 60 minutes for ≥3 nights/week in previous 4 weeks. sWASO will include time spent awake after sleep onset before final awakening + time spent awake in bed attempting to sleep ,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,inc010,inclusion,condition,"[""general""]",condition,=,,,global PSQI score greater than 5;,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,exc001,exclusion,condition,"[""general""]",condition,=,,,"1. Sleep disorders other than insomnia (restless legs syndrome, parasomnias, REM behavior disorder, circadian rhythm sleep-wake disorder, sleep apnea by STOP questionnaire and apnea hypopnea index (AH",0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,exc002,exclusion,condition,"[""general""]",condition,=,,,habitual bedtime before 9pm or morning awakening before 5am;,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,exc003,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of neurological disorders;,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,exc004,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of psychiatric disorders;,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,exc005,exclusion,condition,"[""general""]",condition,=,,,A Beck depression inventory ((BDI-II) score greater than 16);,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,exc006,exclusion,condition,"[""general""]",condition,=,,,Unstable or serious medical conditions;,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,exc007,exclusion,condition,"[""general""]",condition,=,,,"Current, or use within the past month, of psychoactive, hypnotic, stimulant or analgesic medications (except occasionally);",0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,exc008,exclusion,condition,"[""general""]",condition,=,,,"Use of medications that interfere with NA system activity including B-blockers, selective serotonin and norepinephrine reuptake inhibitors (SNRIs) and selective norepinephrine-dopamine reuptake inhibi",0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,exc009,exclusion,condition,"[""general""]",condition,=,,,Hormone replacement therapy;,0.85,2025-11-09T02:20:29.746530,dementia
NCT06694441,exc010,exclusion,condition,"[""general""]",condition,=,,,"Use of medications that affects pupil diameter and responses to light (i.e. antihistamines, anticholinergics, benzodiazepines, narcotics for pain;",0.85,2025-11-09T02:20:29.746530,dementia
NCT06965686,inc001,inclusion,demographic,"[""gender""]",gender,=,all,,* Female sex at birth,0.85,2025-11-09T02:20:29.746530,dementia
NCT06965686,inc002,inclusion,condition,"[""general""]",condition,=,,,Aged between 40-58 years,0.85,2025-11-09T02:20:29.746530,dementia
NCT06965686,inc003,inclusion,condition,"[""general""]",condition,=,,,Late perimenopause or early post-menopause,0.85,2025-11-09T02:20:29.746530,dementia
NCT06965686,inc004,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,Elevated dementia risk characterized by first degree relative with diagnosis of Alzheimer's disease or another dementia,0.85,2025-11-09T02:20:29.746530,dementia
NCT06965686,exc001,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"* Diagnosis of Mild Cognitive Impairment, Alzheimer's or another dementia",0.85,2025-11-09T02:20:29.746530,dementia
NCT06965686,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Diagnosis of other chronic illness or condition that affects cognition (e.g., Axis I psychiatric disorders such as schizophrenia or mood disorders, neurological disorders such as stroke, cancer, traum",0.85,2025-11-09T02:20:29.746530,dementia
NCT06965686,exc003,exclusion,condition,"[""general""]",condition,=,,,Inadequate vision or hearing to engage with intervention materials,0.85,2025-11-09T02:20:29.746530,dementia
NCT06965686,exc004,exclusion,condition,"[""general""]",condition,=,,,Unable or unwilling to provide informed consent,0.85,2025-11-09T02:20:29.746530,dementia
NCT06965686,exc005,exclusion,condition,"[""general""]",condition,=,,,"Iatrogenic menopause (i.e., due to surgery)",0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,inc001,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,(person living with dementia):,0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,inc002,inclusion,demographic,"[""age""]",age,=,,,age 50 or older,0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,inc003,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,a self-reported mild cognitive impairment or dementia diagnosis and mild-moderate dementia severity (confirmed by care partner or collateral),0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,inc004,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,"a care partner or a collateral (a family member, paid caregiver, or close friend who spends at least 8 hours/week with the person living with dementia and speaks fluent English) who consents to join t",0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,inc005,inclusion,condition,"[""general""]",condition,=,,,"English fluency, categorized as not requiring translation into another language. Being non-verbal or having limited verbal ability will not be considered",0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,exc001,exclusion,condition,"[""general""]",condition,=,,,but this condition will be noted.,0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,exc002,exclusion,condition,"[""general""]",condition,=,,,"access to and basic ability to use the videoconferencing platform (Zoom) on a digital device (tablet, telephone or computer) (or access to support therein).

Inclusion criteria (care partner or a coll",0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,exc003,exclusion,condition,"[""general""]",condition,=,,,age 18 and older,0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,exc004,exclusion,condition,"[""general""]",condition,=,,,speaks fluent English,0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,exc005,exclusion,condition,"[""general""]",condition,=,,,"access to and basic ability to use the videoconferencing platform (Zoom) on a digital device (tablet, telephone or computer) (or access to support therein).

Exclusion Criteria (person living with dem",0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,exc006,exclusion,condition,"[""general""]",condition,=,,,Persons living with dementia unable to provide consent or assent. Persons living with dementia who do not have capacity to provide consent but are capable of providing assent will be included if a car,0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,exc007,exclusion,condition,"[""general""]",condition,=,,,Persons living with dementia with severe dementia (classified as being unable to sit up independently and being non-ambulatory within the upper extremities) will be excluded. Being non-verbal or havin,0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,exc008,exclusion,condition,"[""general""]",condition,=,,,"Lack of reliable access to a digital device with Zoom application.

Exclusion criteria (care partner or a collateral):",0.85,2025-11-09T02:20:29.746530,dementia
NCT06221202,exc009,exclusion,condition,"[""general""]",condition,=,,,Lack of reliable access to a digital device with Zoom application.,0.85,2025-11-09T02:20:29.746530,dementia
NCT06976203,inc001,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,"* Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and ",0.85,2025-11-09T02:20:29.746530,dementia
NCT06976203,inc002,inclusion,condition,"[""general""]",condition,=,,,"Participants must have an Mini-Mental State Examination (MMSE) score ranging from 12 through 22, inclusive, at the time of screening.",0.85,2025-11-09T02:20:29.746530,dementia
NCT06976203,inc003,inclusion,condition,"[""general""]",condition,=,,,Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits. The caregiver must also be responsible for re,0.85,2025-11-09T02:20:29.746530,dementia
NCT06976203,inc004,inclusion,condition,"[""general""]",condition,=,,,"Participants on acetyl choline esterase inhibitors (AChEIs) and/or memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the",0.85,2025-11-09T02:20:29.746530,dementia
NCT06976203,exc001,exclusion,condition,"[""general""]",condition,=,,,"* Participants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study re",0.85,2025-11-09T02:20:29.746530,dementia
NCT06976203,exc002,exclusion,condition,"[""general""]",condition,=,,,"Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate t",0.85,2025-11-09T02:20:29.746530,dementia
NCT06976203,exc003,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifyin",0.85,2025-11-09T02:20:29.746530,dementia
NCT06976203,exc004,exclusion,condition,"[""general""]",condition,=,,,Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that could affect safety or interfere with study procedures.,0.85,2025-11-09T02:20:29.746530,dementia
NCT06976203,exc005,exclusion,condition,"[""general""]",condition,=,,,Other protocol-defined Inclusion/Exclusion criteria apply.,0.85,2025-11-09T02:20:29.746530,dementia
NCT05145868,inc001,inclusion,condition,"[""general""]",condition,=,,,* 18-30 years old,0.85,2025-11-09T02:20:29.746530,dementia
NCT05145868,inc002,inclusion,condition,"[""general""]",condition,=,,,Consumed alcohol an average of 2 times per week in last 3 months,0.85,2025-11-09T02:20:29.746530,dementia
NCT05145868,inc003,inclusion,condition,"[""general""]",condition,=,,,At least two instances of heavy episodic drinking in last month,0.85,2025-11-09T02:20:29.746530,dementia
NCT05145868,inc004,inclusion,condition,"[""general""]",condition,=,,,Currently in a romantic relationship,0.85,2025-11-09T02:20:29.746530,dementia
NCT05145868,inc005,inclusion,condition,"[""general""]",condition,=,,,History of IPV perpetration within last 3 months,0.85,2025-11-09T02:20:29.746530,dementia
NCT05145868,inc006,inclusion,condition,"[""general""]",condition,=,,,Willing to provide cell phone number and carrier and receive text messages for 30 days,0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,inc001,inclusion,condition,"[""general""]",condition,=,,,for adults with ID will include:,0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,inc002,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,"ages 18 and older with a prior clinical diagnosis of ID, confirmed by scores \< 70 and + 90% on the Leiter-3 International Performance Scales and/or an adaptive behavior measure using the Vineland Ada",0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,inc003,inclusion,condition,"[""general""]",condition,=,,,"Medical clearance to participate in moderate-to-vigorous physical activity as determined by the American College of Sports Medicine (ACSM) preparticipation algorithm,",0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,inc004,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,Adult does not show clinically elevated symptoms of Alzheimer's Disease (AD)/ Alzheimer's Disease and Related Dementias (ADRD) as indicated by a score of \< 20 on the Dementia Screening Questionnaire ,0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,inc005,inclusion,condition,"[""general""]",condition,=,,,One caregiver/guardian is able and willing to participate.,0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,inc006,inclusion,condition,"[""general""]",condition,=,,,"must tolerate at least 8 hours of daily wear-time of Actigraph device during initial assessment period (4 of 7 days),",0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,inc007,inclusion,condition,"[""general""]",condition,=,,,"must average 20 minutes or less of moderate to vigorous physical activity (MVPA) minutes per day (140 MVPA minutes or less across 7-day period measured during the initial assessment period, and",0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,inc008,inclusion,condition,"[""general""]",condition,=,,,must reside in North Carolina or Arkansas.,0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,exc001,exclusion,condition,"[""general""]",condition,=,,,for adults with ID:,0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Diagnosis of AD, dementia, or related disorders. Participants will not be excluded based on gender, race, or ethnicity. There will be no upper age limit due to the heterogeneity of onset of AD/ADRD in",0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,exc003,exclusion,condition,"[""general""]",condition,=,,,"access to the internet and a mobile device,",0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,exc004,exclusion,condition,"[""general""]",condition,=,,,"has weekly contact with the adult participant with ID,",0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,exc005,exclusion,condition,"[""general""]",condition,=,,,"can converse and read in English to comprehend intervention materials and website content, and",0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,exc006,exclusion,condition,"[""general""]",condition,=,,,"must reside in North Carolina or Arkansas

Inclusion criteria for caregiver will include:",0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,exc007,exclusion,condition,"[""general""]",condition,=,,,"ability to converse and read in English to comprehend and answer interview questions, (2) must care for an adult with ID who is willing to participate in the study,",0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,exc008,exclusion,condition,"[""general""]",condition,=,,,"must reside in North Carolina or Arkansas, and",0.85,2025-11-09T02:20:29.746530,dementia
NCT06740162,exc009,exclusion,condition,"[""general""]",condition,=,,,must attend all study visits with adult with ID.,0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,inc001,inclusion,condition,"[""general""]",condition,=,,,"* Ability of the participant and/or his/her legally authorized representative to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use o",0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,inc002,inclusion,condition,"[""general""]",condition,=,,,Ability to speak and read fluently in English,0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,inc003,inclusion,condition,"[""general""]",condition,=,,,18-89 years old (inclusive),0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,inc004,inclusion,condition,"[""general""]",condition,=,,,Normal or corrected to normal hearing and vision,0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,inc005,inclusion,condition,"[""general""]",condition,=,,,"Meet clinical diagnostic criteria for MCI or Mild AD, according to the criteria outlined above",0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,inc006,inclusion,condition,"[""general""]",condition,=,,,Study partner available for duration of trial participation,0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,inc007,inclusion,condition,"[""general""]",condition,=,,,At least one copy of the APOE ε4 allele,0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,inc008,inclusion,condition,"[""general""]",condition,=,,,An aggregate risk score \> 4 according to the risk analysis method developed by Sabbagh et al. (2017),0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,inc009,inclusion,condition,"[""general""]",condition,=,,,"For individuals who are taking niacin (or a vitamin supplement with niacin) of \>200mg, the completion of a two-week wash-out period",0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,exc001,exclusion,condition,"[""general""]",condition,=,,,"* Current serious or unstable medical or neurological condition that could affect cognitive functioning, as determined by study clinician",0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,exc002,exclusion,condition,"[""general""]",condition,=,,,"Clinically unstable mood or anxiety disorder within 6 months prior to screening, as determined by study clinician",0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,exc003,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Lifetime history of psychotic disorder (i.e. Schizophrenia, Schizoaffective Disorder), as determined by study clinician",0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,exc004,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,Diagnosis of a mitochondrial disorder,0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,exc005,exclusion,condition,"[""general""]",condition,=,,,Any MRI safety contraindications,0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,exc006,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of drug hypersensitivity or intolerance to NR,0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,exc007,exclusion,condition,"[""general""]",condition,=,,,Transient ischemic attack or stroke within 1 year prior to screening,0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,exc008,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"History of alcohol or substance abuse within prior year, as determined by study clinician and urine toxicology screen",0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,exc009,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"History of head injury rated as moderate or worse, per DSM-5 criteria",0.85,2025-11-09T02:20:29.746530,dementia
NCT05245903,exc010,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,History of seizure within prior 10 years,0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,inc001,inclusion,condition,"[""general""]",condition,=,,,1. Must be between the ages of 55 - 85 and provide valid informed consent.,0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,inc002,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,Participant must receive a diagnosis of Mild Cognitive Impairment after a careful cognitive and functional evaluation by a clinician.,0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,inc003,inclusion,condition,"[""general""]",condition,=,,,Functional Activities Questionnaire (FAQ) score of 8 or less and self-reported ability to function independently,0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,inc004,inclusion,condition,"[""general""]",condition,=,,,Montreal Cognitive Assessment (MoCa) score is between 18-25,0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,inc005,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,"Participant must have a CDR score of .5 on the Clinical Dementia Rating scale (CDR), which includes an assessment of function and is often used to distinguish MCI from dementia.",0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,inc006,inclusion,condition,"[""general""]",condition,=,,,Must have an informant that will be utilized over the course of the 24 week study (must be the same person throughout study),0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,inc007,inclusion,condition,"[""general""]",condition,=,,,Participant must pass a test of consent comprehension,0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,inc008,inclusion,condition,"[""general""]",condition,=,,,Must be interested in using CBD to help with cognitive function,0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,inc009,inclusion,condition,"[""general""]",condition,=,,,Must plan on living in the Denver metro area over the next 6 months,0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,inc010,inclusion,condition,"[""general""]",condition,=,,,Able to attend in-person visits at the study site,0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,exc001,exclusion,condition,"[""general""]",condition,=,,,"1. Any other central nervous system (CNS) disease that would be expected to affect cognition, Parkinson's disease, multiple sclerosis.",0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,exc002,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Any history of brain injury (e.g., concussion with significant loss of consciousness)",0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,exc003,exclusion,condition,"[""general""]",condition,=,,,Any significant systemic illness or unstable medical condition,0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,exc004,exclusion,condition,"[""general""]",condition,=,,,"Current use of Parkinson's medications, antipsychotic medications, anti-seizure medications, or anticholinergic medications",0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,exc005,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Current or lifetime diagnosis of a schizophrenia spectrum disorder, psychotic disorder, bipolar disorder type I \& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic",0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,exc006,exclusion,condition,"[""general""]",condition,=,,,Participation in other clinical studies involving neuropsychological measures being collected more than one time per year.,0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,exc007,exclusion,condition,"[""general""]",condition,=,,,"Reported use of other drugs (cocaine, opiates, methamphetamine, MDMA) in the past 60 days or test positive on a urine test for those drugs of abuse at baseline.",0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,exc008,exclusion,condition,"[""general""]",condition,=,,,"Report using cannabis, including products with or without CBD, more than four times per month.",0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,exc009,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Recent history of, or meets criteria for major depression with suicidal ideation.",0.85,2025-11-09T02:20:29.746530,dementia
NCT05822362,exc010,exclusion,condition,"[""general""]",condition,=,,,Reports use of medical CBD.,0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,inc001,inclusion,condition,"[""general""]",condition,=,,,"1. Men or women between the ages of 50 and 80 years, inclusive at the time of screening.",0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,inc002,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,Clinical diagnosis of Parkinson's disease as defined by the United Kingdom Parkinson's disease (PD) Society Brain Bank Clinical Diagnostic Criteria and Movement Disorder Society Parkinson's disease Cr,0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,inc003,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,"Maintenance on stable Parkinson's disease therapy for at least 28 days prior to Screening/Visit 1 through treatment period to Day 42, with demonstratable medication efficacy as assessed by the Investi",0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,inc004,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,"Severity of Parkinson's disease symptoms assessed by Hoehn and Yahr Staging score ≤3.0 (assessed in the ""ON"" state).",0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,inc005,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,Maintenance on permitted stable non-Parkinson's disease therapy for at least 28 days prior to Day 1 through the treatment period to Day 42.,0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,inc006,inclusion,demographic,"[""gender""]",gender,=,all,,"Female participants of childbearing potential must have a negative urine pregnancy test at Screening and baseline, as well as be non-lactating and must agree to use a highly effective method of contra",0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,inc007,inclusion,demographic,"[""gender""]",gender,=,all,,Male participants must be sterile or sexually inactive or agree not to father a child during the study and for 1 month after the last dose of study medication and must agree to use a barrier method fo,0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,inc008,inclusion,condition,"[""general""]",condition,=,,,"Adequate visual, hearing, cognitive and physical ability and willingness to comply with study drug administration, scheduled visits, treatment plan, laboratory tests, and other study-related procedure",0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,inc009,inclusion,condition,"[""general""]",condition,=,,,Institutional Review Board/Ethics Committee-approved consent form signed and dated by the participant,0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,exc001,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,1. Diagnosis of secondary or atypical parkinsonism,0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,exc002,exclusion,condition,"[""general""]",condition,=,,,"Severe or disabling fluctuations or dyskinesias that would, in the opinion of the Investigator, interfere with completion of the study",0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,exc003,exclusion,condition,"[""general""]",condition,=,,,"Previous surgical procedure for Parkinson's disease (e.g. Duopa, deep brain stimulation)",0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,exc004,exclusion,condition,"[""general""]",condition,=,,,Clinically significant cognitive impairment with a Montreal Cognitive Assessment score \<18,0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,exc005,exclusion,condition,"[""general""]",condition,=,,,Has a history or current evidence of long QT syndrome,0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,exc006,exclusion,condition,"[""general""]",condition,=,,,Has bradycardia or tachycardia on the electrocardiogram (ECG) at Screening,0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,exc007,exclusion,condition,"[""general""]",condition,=,,,"Clinical or laboratory findings consistent with another primary neurodegenerative disease or cognitive disorder other than Parkinson's disease, including but not limited to, frontotemporal lobar disea",0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,exc008,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Suicidality, defined as active suicidal thoughts or ideation or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide",0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,exc009,exclusion,condition,"[""general""]",condition,=,,,Currently active major depression as determined by Beck Depression Inventory (BDI)-II score of \>19,0.85,2025-11-09T02:20:29.746530,dementia
NCT06309147,exc010,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Has a history or current diagnosis of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the Diagnostic and Sta",0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,inc001,inclusion,condition,"[""general""]",condition,=,,,"* Documented/Verified TBI (ACRM Criteria) (eg, motor vehicle (MV) occupant, MV pedestrian/cyclist, fall, other non-intentional, violence/assault)",0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,inc002,inclusion,condition,"[""general""]",condition,=,,,"A documented moderate to severe TBI defined as: Glasgow Coma Scale (GCS) \< 13, or loss of consciousness (LOC) \> 30 minutes, or posttraumatic amnesia (PTA) \> 24 hours or intracranial neuroimaging ab",0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,inc003,inclusion,demographic,"[""age""]",age,between,"18,80",years,Between the age 18 - 80 year-old,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,inc004,inclusion,condition,"[""general""]",condition,=,,,≤ 1 week postinjury,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,inc005,inclusion,condition,"[""general""]",condition,=,,,Acute brain CT for clinical care,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,inc006,inclusion,condition,"[""general""]",condition,=,,,Admitted to the hospital for TBI,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,inc007,inclusion,condition,"[""general""]",condition,=,,,Visual acuity/hearing adequate for testing,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,inc008,inclusion,condition,"[""general""]",condition,=,,,Fluent in English or Spanish,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,inc009,inclusion,condition,"[""general""]",condition,=,,,Patient or LAR ability to provide informed consent,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,exc001,exclusion,condition,"[""general""]",condition,=,,,* Age greater or less than the range 18-80 years,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,exc002,exclusion,condition,"[""general""]",condition,=,,,Significant polytrauma that would interfere with follow-up and outcome assessment,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,exc003,exclusion,condition,"[""general""]",condition,=,,,"Major debilitating baseline mental health disorders (e.g., schizophrenia, bipolar disorder, severe depression with active suicidal thoughts at the time of evaluation) that would interfere with follow-",0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,exc004,exclusion,condition,"[""general""]",condition,=,,,"Major debilitating neurological disease (e.g., stroke, CVA, dementia, tumor) impairing baseline awareness, cognition, or validity of follow-up and outcome assessment.",0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,exc005,exclusion,condition,"[""medical_history""]",medical_history,excludes,present,,"Significant history of pre-existing conditions that would interfere with follow-up and outcome assessment (e.g., active substance abuse, alcoholism, HIV/AIDs, end-stage cancers, learning disabilities,",0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,exc006,exclusion,condition,"[""general""]",condition,=,,,Patients on psychiatric hold,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,exc007,exclusion,condition,"[""general""]",condition,=,,,Prisoners or patients in custody,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,exc008,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,Pregnancy in female subjects,0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,exc009,exclusion,condition,"[""general""]",condition,=,,,"Low likelihood of follow-up (e.g., participants or family indicating low interest, residence in another state or country, homeless or lack of reliable contacts)",0.85,2025-11-09T02:20:29.746530,dementia
NCT06480838,exc010,exclusion,condition,"[""general""]",condition,=,,,"Current participant in an interventional trial (e.g., drug, device, behavioral)",0.85,2025-11-09T02:20:29.746530,dementia
NCT04099823,inc001,inclusion,condition,"[""general""]",condition,=,,,"* A healthy control will be defined as an otherwise healthy person who does not have a medical condition that affects brain function or have problems with concentration, memory, balance, or coordinati",0.85,2025-11-09T02:20:29.746530,dementia
NCT04099823,inc002,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,Patients who have a suspected diagnosis of altered CSF dynamics including but not limited to normal pressure hydrocephalus will be referred to Dr. Cogswell by their care team to be included in the stu,0.85,2025-11-09T02:20:29.746530,dementia
NCT04099823,inc003,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,"Similarly, patients with impaired cognitive function including but not limited to Alzheimer's disease will be referred to Dr. Cogswell by their care team to be included in the study.",0.85,2025-11-09T02:20:29.746530,dementia
NCT04099823,exc001,exclusion,condition,"[""general""]",condition,=,,,* Subjects with non-MRI compatible devices,0.85,2025-11-09T02:20:29.746530,dementia
NCT04099823,exc002,exclusion,condition,"[""general""]",condition,=,,,required sedation,0.85,2025-11-09T02:20:29.746530,dementia
NCT04099823,exc003,exclusion,condition,"[""pregnancy_status""]",pregnancy_status,=,pregnant,,women who may be pregnant will be excluded.,0.85,2025-11-09T02:20:29.746530,dementia
NCT04099823,exc004,exclusion,condition,"[""general""]",condition,=,,,The first 10 subjects with normal pressure hydrocephalus will not have previously been shunted.,0.85,2025-11-09T02:20:29.746530,dementia
NCT05205980,inc001,inclusion,condition,"[""general""]",condition,=,,,* Participants must be at least 65 years old;,0.85,2025-11-09T02:20:29.746530,dementia
NCT05205980,inc002,inclusion,condition,"[""diagnosis"", ""dementia""]",diagnosis,=,dementia,,Participants have a clinical diagnosis of probable AD;,0.85,2025-11-09T02:20:29.746530,dementia
NCT05205980,inc003,inclusion,condition,"[""general""]",condition,=,,,Participants can read and understand English;,0.85,2025-11-09T02:20:29.746530,dementia
NCT05205980,inc004,inclusion,condition,"[""general""]",condition,=,,,Participants must be able to walk independently at least 25 feet;,0.85,2025-11-09T02:20:29.746530,dementia
NCT05205980,inc005,inclusion,condition,"[""general""]",condition,=,,,Participants must be able to stand independently for at least 30 seconds;,0.85,2025-11-09T02:20:29.746530,dementia
NCT05205980,inc006,inclusion,condition,"[""general""]",condition,=,,,Participants must have a Monteral Cognitive Assessment score of 11-21 or Mini Mental Status Examination score between 18 and 23.,0.85,2025-11-09T02:20:29.746530,dementia
NCT05205980,exc001,exclusion,condition,"[""general""]",condition,=,,,* Individuals have ever experienced perturbation training;,0.85,2025-11-09T02:20:29.746530,dementia
NCT05205980,exc002,exclusion,condition,"[""general""]",condition,=,,,Individuals have hypotension or uncontrolled hypertension;,0.85,2025-11-09T02:20:29.746530,dementia
NCT05205980,exc003,exclusion,condition,"[""general""]",condition,=,,,Individuals exhibit osteoporosis;,0.85,2025-11-09T02:20:29.746530,dementia
NCT05205980,exc004,exclusion,condition,"[""general""]",condition,=,,,"Participants suffer from coexisting psychiatric disorders, or other neurological conditions, or injuries, etc.",0.85,2025-11-09T02:20:29.746530,dementia
